

HOME ADDRESS:

5503 South Island Park Drive
Manotick, Ontario K4M 1J2
Phone: (613) 692-6194

OFFICE ADDRESS:

Department of Pathology and Laboratory
Medicine
University of Ottawa, Faculty of Medicine
4155-451 Smyth Road
Ottawa, Ontario K1H 8M5
Phone: (613) 562-5422
adebold@bell.net

EDUCATION

- 1961 - 1967 National University of Córdoba, Argentina
1968 Professional Degree: Clinical Biochemist
1968 - 1973 School of Graduate Studies, Queens University, Kingston, Ontario, Canada
1971 M.Sc. (Experimental Pathology) "Studies on the Relationship between the Catecholamine Distribution in the Atrium and the Specific Granules Present in Atrial Muscle Cells"
1973 Ph.D. (Experimental Pathology) "The Relationship Between Morphology and Function in the Atrial Cardiocyte. A study With Emphasis on the Secretory Characteristics of the Mammalian Atrium"

PROFESSIONAL APPOINTMENTS

- 1974 Laboratory Scientist,
Pathology Laboratory, Hotel Dieu Hospital, Kingston, Ontario, Canada.
- 1974 Assistant Professor of Pathology,
Department of Pathology, Faculty of Medicine, Queen's University, Kingston,
Ontario, Canada (Tenured, 1981).
- 1982 Associate Professor of Pathology, Faculty of Medicine, Queen's University,
Kingston, Ontario, Canada.
- 1985 Professor of Pathology,
Faculty of Medicine, Queen's University, Kingston, Ontario, Canada.
- 1986-1993 Director of Research, University of Ottawa
Heart Institute Research Centre, Ottawa Civic Hospital.
- 1989-1995 Distinguished Research Professor,
Heart and Stroke Foundation of Ontario.
- 1986-1995 Adjunct Professor of Pathology,
Queen's University, Kingston, Ontario, Canada.
- 1986-2013 Professor of Pathology and Laboratory Medicine Faculty of Medicine, University of
Ottawa, Ottawa, Ontario, Canada
- 1986-2013 Cross-appointment, Department of Cellular and Molecular Medicine, Faculty of

Medicine, University of Ottawa, Ottawa, Ontario, Canada

1986-2013 Director, Cardiovascular Endocrinology Laboratory University of Ottawa Heart Institute, Ottawa, Ontario, Canada

1986-2013 Active Scientific Staff, Department of Surgery, Division of Cardiac Surgery, The Ottawa Hospital, Ottawa, Ontario, Canada

July 2013 Professor Emeritus, University of Ottawa, Canada

DISTINCTIONS

Scientific Prizes

- Queen's University Prize for Excellence in Research, 1985. Ernest C. Manning Principal Award, 1986.
- Canadian Cardiovascular Society Research Achievement Award, 1986. American Society for Hypertension Research Award, 1986.
- Gairdner Foundation International Award, 1986.
- The Royal Society of Canada McLaughlin Medal in Medical Research, 1988. International Society for Hypertension Research Achievement Award, Montreal 1990. Paraná Heart Foundation Golden Heart, 1993.
- CIBA Award in Hypertension Research, Council for High Blood Pressure Research, American Heart Association, Chicago, 1994
- Canadian Institutes of Health Research-Canadian Medical Association Journal Top Canadian Achievements in Health Research Award, 2009
- Grand Prix Scientifique, Fondation Lefoulon-Delalande, Institute de France, 2014

Academic Distinctions

- Distinguished Visiting Professor, 1988 Biological Colloquium, University of Western Ontario, London, Ontario.
- Honorary Professor, National University of Tucumán, Argentina, 1988. Honorary Member, Medical Association of Córdoba, Argentina, 1988.
- Distinguished Visiting Professor, Catholic University of Córdoba, Argentina, 1988.
- Honorary Member, Society for Clinical Pharmacology and Therapeutics, Córdoba, Argentina, 1988.
- Honorary Member, Biochemical College, Paraná, Argentina, 1988.
- Distinguished Research Professor, Heart and Stroke Foundation of Ontario, 1988.
- Visiting Professor, Cleveland Clinic Foundation, Fifth Annual Merck, Sharp and Dohme Lectureship, February 1990.
- Honorary Professor of the University of Buenos Aires, Buenos Aires, 1991 Honorary Professor, National University of Córdoba, Argentina, 1993
- Distinguished Lecturer, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, 1993.
- Member of the Advisory Board, Faculty of Medicine of Rosario at Paraná, Argentina. Honorary Professor, Universidad Nacional Del Litoral, Santa Fe, Argentina, 1996
- The Houssay Lecture (In commemoration of the 50Th Anniversary of the Nobel Prize to A.

Houssay), University of Buenos Aires, November, 1997

- Doctor Honoris Causa, National University of Entre Rios, Argentina, 2001
- “Living Legend” Award, International Society of Cardiothoracic Surgeons, Ottawa, 2006
- Doctor Honoris Causa, Catholic University of Cordoba, Argentina, 2007
- Doctor Honoris Causa, National University of Cordoba, Argentina, 2010
- Excellence in Research and Teaching Award. University of Ottawa, September 30, 2010
- Member of the Canadian Medical Hall of Fame, 2014
- Invited Speaker, 400th Anniversary of the Universidad Nacional de Córdoba and 100th Anniversary of the Hospital Nacional de Clínicas, Córdoba, 2013.
- Opening Lecturer, Conference on Bioactive Peptides for Cell-Cell Communication, Kyoto, Japan, 2014
- Opening Lecturer, 46th Brazilian Congress of Pharmacology and Experimental Therapeutics, Fortaleza, Brazil, 2014

Governmental Distinctions

- Officer of the Order of Canada, 1993
- Legion of Merit of the province of Entre Ríos, Argentina, 1993 Distinguished Citizen, Paraná, Argentina, 1993
- Citizenship Judge, Citizenship Ceremony, Ottawa, November 10, 1995
- Honouree of the Speaker of the House of Commons Distinguished Canadians Initiative, and Macleans magazine, House of Parliament, Ottawa, September 19, 1995
- Argentinean Scientist Abroad and Member of the CONICET, Argentina, 1995 Member of the National Cardiovascular Institute, Argentina, 1995
- Queen Elizabeth II Golden Jubilee Medal
- 2002 Queen Elizabeth II Diamond Jubilee Medal, 2012

Other Distinctions

- The Macleans Honour Roll, 1986.
- Knight Commander, Knights of Malta, 1987.
- "Citation Classic", Institute for Scientific Information for receiving more than 1200 citations to 1989 on the original ANF discovery report.
- "Citation Classic", Institute for Scientific Information for receiving more than 650 citations to 1992 on the first sequence of ANF.
- Prize To Excellence, Instituto Argentino de la Excelencia, Paraná, December 12, 1995, Argentina
- First of the Top Ten Research Accomplishments Funded by the Ontario Heart and Stroke Foundation in the Past 50 Years, 2002
- Listed in Canadian Who's Who
- Listed in American Men and Women of Science
- One hundred and sixty six invited national and international lectures

MOST SIGNIFICANT TECHNICAL AND SCIENTIFIC CONTRIBUTIONS

Technical contributions:

1. First technique to isolate atrial granules by preparative ultracentrifugation (Cardiovasc.Res.7: 351, 1973)

2. First technique to specifically demonstrate atrial granules at the light microscopic level (Stain Technol 50:203,1975)
3. First unbiased morphometric technique to quantitate atrial granules and demonstration that granule number change according to salt load thus providing the basis for the discovery of ANF (J.Molec.Cell Cardiol. 10:717, 1978; Proc.Soc.Exptl.Biol.Med. 161:508, 1979)
4. First method to isolate and purify ANF leading to first report of sequence (Proc.Soc.Exptl.Biol.Med. 170: 133, 1982; Life Sci. 33: 297, 1983; Biochem. Biophys. Res. Commun., 117:859-865, 1983; Science 228: 323, 1985)
5. Development and characterization of a radioimmunoassay for ANF (Clin.Biochem. 22: 111989)
6. Development and characterization of atrial preparations to study heart endocrine function (Am.J.Physiol. 256: H1588, 1989; Endocrinology 137: 137, 1996)
7. Development and characterization of a QC-RT-PCR technique for natriuretic peptides based on a combination of heterologous DNA containing synthetic specific sequences and an internal standard/competitor using specific rcRNAs (Hypertension 30: 1342-1347, 1997).
8. Development of a serum-free mixed lymphocyte reaction culture to study regulation of BNP by cytokines (J Mol Cell Cardiol. 36:505-513, 2004)

Scientific contributions:

1. Discovery of a new cell type in the pars intermedia of the pituitary gland and description of the anatomical basis for circulation in this avascular tissue (Cell Tissue Res. 207:347, 1980)
2. Discovery, isolation and purification and sequencing of the cardiac polypeptide hormone ANF thus proving an endocrine function for the heart (Life Sci. 28: 89, 1981; Biochem. Biophys. Res. Commun., 117:859-865, 1983. Science, 230:767, 1985)
3. Demonstration of the storage function of atrial granules for ANF thus explaining the atrial phenotype (Can.J.Physiol.Pharmacol. 60:324, 1982)
4. Demonstration that ANF mediates the mineralocorticoid escape phenomenon thus explaining a long-standing physiological puzzle (J.Clin.Invest. 94: 1938, 1994)
5. Demonstration that the cardiac mesothelium synthesizes and releases endothelin thus providing a testable hypothesis regarding mediators of cell-cell interactions in the determination of the cardiac phenotype (J.Cardiovasc.Pharmacol. 24: 715, 1994)
6. Demonstration of a dual endocrine-hemodynamic load determinant of natriuretic peptide gene expression and secretion (Circulation 93: 2059, 1996)
7. Discovery of tissue specific, opposite regulation of renal and cardiac ANF in DOCA salt hypertension thus providing an hypothesis regarding the failure of mineralocorticoid escape in mineralocorticoid hypertension (Hypertension, 30: 1342-1347, 1997)
8. Discovery of specific, opposite changes in renal ANF gene expression in mineralocorticoid versus renovascular hypertension (Hypertension, 33:1342-7, 1998)
9. Discovery of selective upregulation of BNP related to T-lymphocyte-mediated inflammation in human cardiac allograft transplants leading to a screening test and a patent (Circulation, 100: 287-91, 1999)
10. Described the property of mixed lymphocyte reaction conditioned medium of selectively upregulating BNP gene expression thus implicating BNP in an immunoregulatory function (J Mol Cell Cardiol. 36:505-513, 2004)
11. Provided mechanistic explanation of upregulation of BNP gene expression by pro-inflammatory cytokines at the transcriptional level (J Mol Cell Cardiol. 36:505-513, 2004)
12. Discovery of Go protein signaling in the regulation of stretch-induced ANF secretion (Endocrinology 145:5313-21, 2004) thus demonstrating the first specific member of the

stretch- secretion coupling signaling cascade.

13. Description of RASD1 as a modulator of ANF secretion (Am J Physiol Heart Circ Physiol. 302: H1826, 2012)

14. Description of repression-derepression of baseline ANF secretion by manipulation of effectors downstream of Gq protein signaling, including phospholipase A (Am J Physiol Heart Circ Physiol 304:H1328-36, 2013)

EXPERIENCE

Teaching:

1961 - 1962 Demonstrator, Department of Physics,
National University of Córdoba, Argentina.

1964 - 1967 Demonstrator, Department of Normal and Pathological Histology,
National University of Córdoba, Argentina.

1971 - 1972 Demonstrator, Electron Microscopy Course for Residents,
Department of Pathology, Queen's University, Kingston, Ontario

1986 - 1990 Honours Course "Special Topics in Endocrinology"
Department of Physiology, University of Ottawa

1994 - 1997 Graduate course "Cardiovascular System": Regulation of Blood Pressure and Cardiac
Output, Department of Physiology, University of Ottawa

2004 - present Graduate Course "Pathology for Graduate Students", Department of Cell and
Molecular Medicine

Service:

1966 - 1968 Resident, Central Laboratory, Hospital Nacional de Clínicas, Córdoba, Argentina.

1967 - 1968 Chief Resident, Central Laboratory, Hospital Nacional de Clínicas, Córdoba,
Argentina.

1974 - 1985 a. Direction of Electron Microscopy Unit, Hotel Dieu Hospital, Kingston, Ontario,
Canada.
b. Supervision and Development Work in Therapeutic Drug Monitoring
Laboratory, Hotel Dieu Hospital, Kingston, Ontario, Canada.
c. Co-Author of Proposal for Regional Therapeutic Drug Monitoring Laboratory,
Hotel Dieu Hospital, Kingston, Ontario, Canada.

Research:

1968 - 1969 Light and electron microscopic studies on the embryonal and adult pancreatic beta
cell.

Studies on in vitro insulin release by embryonal and adult beta cells.

Studies on in vitro insulin release by human pancreatic tumours.

Morphological studies on the adult cardiac muscle cell phenotype in different species.

1970 - 1973 Fractionation of cardiac muscle tissue by preparative ultracentrifugation. Characterization of the different fractions by marker enzymes and electron microscopy. Development of the first isolation procedure to obtain specific atrial granules from atrial muscle on a preparative scale.

Development of a micromethod to process subcellular fractions for electron microscopy.

Biochemical and histochemical studies on the distribution of norepinephrine and epinephrine in the rat atrium. Improvement of the silver methenamine technique for the demonstration of biogenic amines at the electron microscopic level.

First biochemical and autoradiographic studies on the fate of newly synthesised protein in atrial and ventricular heart muscle.

1974 - 1986 Studies on the mechanism of norepinephrine depletion in congestive heart failure.

Morphometric and histochemical studies on the atrial myocardium. Development of the first method to specifically stain atrial granules at the light microscopic levels and of the first method to measure the degree of granulation of atrial cardiocytes without bias.

Histochemistry of parenchymal stores of catecholamines in endocrine glands.

Studies on the subcellular distribution of heart renin-like activity.

Morphofunctional studies on the pars intermedia of the adenohipophysis. First description of a canaliculi system within this avascular gland.

Development of a new silver impregnation technique and discovery (with M.L. Kuroski de Bold) stellate cells of the pars intermedia of the adenohipophysis and their microanatomical relation to the secretory cells and canaliculi system.

Discovery of the diuretic and natriuretic properties of atrial myocardium homogenates: Atrial Natriuretic Factor (ANF).

First isolation, purification and sequencing of ANF. Cloning of ANF cDNA.

Studies on ANF post-translational processing in whole tissue and in superfused, cultured adult atrial cardiocytes. Studies on the requirements for ANF release and associated stimulus transduction. Effect of stretch and endocrine stimulation.

Characterization of intracellular natriuretic peptide pools in atrial cardiocytes.

Several advances in the elucidation of the endocrine function of the heart.

Control of ANF and related genes expression. during muscle phenotype induction in teratocarcinoma-derived P-19 cells.

Characterization of stretch-secretion coupling in cardiac atria and its relation to proto-oncogene gene expression, contractile protein isoform switching and cardiac hypertrophy.

Neurohumoral changes in congestive heart failure, orthotopic heart transplantation and coronary artery disease.

Investigation of the administration of neutral endopeptidase inhibitors as a new therapeutic modality in congestive heart failure and hypertension.

First demonstration of the role of ANF in the mineralocorticoid escape phenomenon.

Mesothelium-cardiocyte interactions in phenotype determination.

ANF-endothelin interactions in their purported paracrine roles.

Expression of natriuretic peptides in human coronary arteries. Investigations using QC-PCR and in situ hybridization.

Discovery of selective upregulation of BNP in acute cardiac allograft rejection in humans leading to a non-invasive screen test for rejection.

First to describe selective upregulation of BNP by cytokines.

First description of the role of Go proteins in the regulation of ANF secretion.

ELECTED FELLOW

- Royal Society of Physicians and Surgeons (C), 1988 Royal Society of Canada, 1988
- Academy of Medicine, Cordoba, Argentina 1996
- American Association for the Advancement of Science, 1997 International Academy of Cardiovascular Sciences, 2002 American Heart Association Academy, 2003
- Fellow Emeritus, International Academy of Cardiovascular Sciences, 2012 National Academy of Sciences of Argentina, 2013

CONSULTATION

Study Panel, Atrial Natriuretic Factor, for the U.S. National Institutes of Health.

Study Panel, Hypertension SCOR, Cornell University for the U.S. National Institutes of Health

Research and Development Groups in Physiology, Faculty of Medicine, University of Buenos Aires, Argentina for the University Secretary for Science and technology of the University of Buenos Aires

Research Institute in Hypertension (ININCA) for the University Secretary for Science and Technology of the University of Buenos Aires

Secretary of Science and Technology for the Cabinet, Executive Branch, Government of Argentina

Syn-X Pharma Biorexis

BOARD MEMBERSHIPS

- National Research Council, Member of Executive Council, 1987-1990
- Ontario Heart and Stroke Foundation, Member of Board of Directors, 1987-1990 University of Ottawa Heart Institute Advisory Board, 1986 - 1993
- Heart Institute Research Corporation, Member of the Board of Trustees, 1987-1992 Canadian Council for Animal Care, 2001-2007

MEMBERSHIP IN EDITORIAL BOARDS

1983 - 1986 Hypertension
1986 - 1999 American Journal of Hypertension
1993 - 1996 Endocrinology
2000- Science, Education and Technology (ISSN 0327-5566) National University of Entre Ríos, Argentina, Publisher
2003- Revista Medica de la Universidad Nacional de Córdoba
2004- Physiological Mini-Reviews
2005- Heart Failure Monitor
2011- Endocrinology Connections (European Endocrine Society, Senior Editor)

SYMPOSIUM ORGANIZER

Ten Years of ANF research Ottawa, July 1991 Natriuretic Peptides and Vasopeptidase Inhibitors. Ottawa, July 2000.	Vasoactive Peptides American Physiological Society North-South Initiative Mar del Plata, Argentina, November 2003	Organizing Committee XXII Congreso Latinoamericano e Ibero- Americano de Ciencias Fisiológicas Buenos Aires, November 4-7, 2006
Organizer Cardiac Hormones as Biomarkers & Therapeutic Agents 2006 World Congress of Cardiothoracic Surgery	30 Years of ANF Research Satellite Symposium, 23rd International Society of Hypertension Meeting Ottawa, September 22–24, 2010	

CONSULTATION

Order of Canada, Rideau Hall,
Ottawa Syn-X Pharma
BioRexi

PATENTS

Atrial Natriuretic Factor	578889	Australia
	1241646	Canada
	4663437	USA
	4647455	USA
	4761469	USA
	459079	Canada
	58243132	Japan
	83307877.7	EU
Predicting and Detecting Cardiac Allograft Rejection	6117644	USA
Monoclonal antibodies against N-terminus BNP	10/299,606 and 10/359,046	USA
N-Atrial Natriuretic Factor Analogue.	8,008,257	USA

OTHER CONTRIBUTIONS

Founding of Interscientia; a web-based publication to link high profile Latin-American scientists.

Founding of FECIEN; a non-profit organization to inspire young students into a scientific career in Argentina.

Conferences to students and the lay public through different media.

PUBLICATIONS**FULL PAPERS**

1. Rabbit Pancreatic Cell. Morphological and Functional Studies During Embryonal and Post-Natal Development. Bencosme, S.A., Wilson, M.B., Aleyassine, H., de Bold, A.J., and de Bold, M.L. *Diabetologia*, 6:399-411, 1970.
2. Studies on the Relationship between the Catecholamine Distribution in the Atrium and the Specific Granules Present in Atrial Muscle Cells. I. Isolation of a Purified Specific Granule Subtraction. de Bold, A.J., and Bencosme, S.A. *Cardiovas. Res.*, 7:351-363, 1973.
3. Studies on the Relationship between the Catecholamine Distribution in the Atrium and the Specific Granules Present in Atrial Muscle Cells. II. Studies on the Sedimentation Pattern of

- Atrial Noradrenaline and Adrenaline. de Bold, A.J., and Bencosme, S.A. *Cardiovas. Res.*, 7:364-369, 1973.
4. Autoradiographic Analysis of Label Distribution in Mammalian Atrial and Ventricular Cardiocytes After Exposure to Tritiated Leucine. de Bold, A.J., and Bencosme, S.A. In: *Recent Advances in Studies on Cardiac Structure and Metabolism*, Vol. 8, University Park Press, Baltimore, 1975.
 5. Selective Light Microscopic Demonstration of the Specific Granulation of the Rat Atrial Myocardium by Lead-Haematoxylin- Tartrazine. de Bold, A.J., and Bencosme, S.A. *Stain Technology*, 50:203-205, 1975.
 6. An Improved Method for the Production of Experimental Congestive Heart Failure in the Guinea Pig. Ling, E.T., and de Bold, A.J. *Lab. Animals*, 10:285-289, 1976.
 7. Demonstration of Specific Atrial Granules by Aldehyde Fuchsin. Raymond, J.J., de Bold, A.J., and Bencosme, S.A. *Proc. Microscopical Soc. Canada*, 3:92, 1976.
 8. Demonstration of a Tryptaminergic Mechanism in the Rat-Cell. Pulido, O., de Bold, A.J., de Bold, M.L., and Bencosme, S.A. *Experientia*, 33:268, 1977.
 9. Morphometric Assessment of Granulation in Rat Atrial Cardiocytes: Effect of Age. de Bold, A.J. *J. Mol. Cell Cardiol.*, 10:717-724, 1978.
 10. Intracellular Pancreatic Cell Serotonin and the Dynamics of Insulin Release. Pulido, O.M., Bencosme, S.A., de Bold, M.L., and de Bold, A.J. *Diabetologia*, 15:197-204, 1978.
 11. Atrial Specific Granules of the Rat Heart. Light Microscopic Staining and Histochemical Reactions. de Bold, A.J., Raymond, J.J., and Bencosme, S.A. *J. Histochem. Cytochem.*, 26:1094-1102, 1978.
 12. Heart Atria Granularity. Effects of Changes in Water Electrolyte Balance. de Bold, A.J. *Proc. Soc. Exptl. Biol. Med.*, 161:508-511, 1979.
 13. Structural Relationships Between Parenchymal and Stromal Elements in the Pars Intermedia of the Rat Adenohypophysis as Demonstrated by Extracellular Space Markers. de Bold, A.J., de Bold, M.L., and Kraicer, J. *Cell and Tissue Research*, 207:347-359, 1980.
 14. Pyruvate Kinase Levels in the Lymphocytes of Malnourished Anergic Patients. Wren, S.F.G., Crowe, M., Lowe, P.J., and de Bold, A.J. *J. Surgical Research*, 29:203-208, 1980.
 15. A Rapid and Potent Natriuretic Response to Intravenous Injection of Atrial Myocardial Extract in Rats. de Bold, A.J., Borenstein, H.B., Veress, A.T., and Sonnenberg, H. *Life Sciences*, 28:89-94, 1981.
 16. Myocardial Glycolytic and Gluconeogenic Enzyme Activity During Cardiopulmonary Bypass in Humans. Wren, S.F.G., Salerno, T.A., Crowe, M., and de Bold, A.J. *Can. J. Surg.*, 24:604-605, 1981.

17. Intrarenal Localisation of the Natriuretic Effect of Cardiac Atrial Extract. Sonnenberg, H., Cupples, W.A., de Bold, A.J., and Veress, A.T. In: Hormonal Regulation of Epithelial Transport of Ions and Water, (Eds. Scott, W.N., and Goodman, D.B.P.), The New York Academy of Sciences, New York, pp. 213-214, 1981.
18. Tissue Fractionation Studies on the Relationship Between an Atrial Natriuretic Factor and Specific Atrial Granules. de Bold, A.J. *Can. J. Physiol. Pharmacol.*, 60:324-330, 1982.
19. Atrial Natriuretic Factor of the Rat Heart. Studies on Isolation and Properties. de Bold, A.J. *Proc. Soc. Exptl. Biol. Med.*, 170:133-138, 1982.
20. Intrarenal Localisation of the Natriuretic Effect of Cardiac Atrial Extract. Sonnenberg, H., Cupples, W.A., de Bold, A.J., and Veress, A.T. *Can. J. Physiol. Pharmacol.*, 60:1149-1152, 1982.
21. Natriuretic Activity of Extracts Obtained from Hearts of Different Species and from Various Rat Tissues. de Bold, A.J., and Salerno, T.A. *Can. J. Physiol. Pharmacol.*, 61:127-130, 1983.
22. Cardionatrin* I. A Novel Heart Peptide with Potent Diuretic and Natriuretic Properties. de Bold, A.J., and Flynn, T.G. *Life Sciences*, 33:297-302, 1983. *: cardionatrin is an early name for ANF.
23. Cardionatrin I. de Bold, A.J. In: *Annual Drug Refer*, Vol. 5, J.R. Prous Press, Barcelona, 1983.
24. The Amino Acid Sequence of an Atrial Peptide with Potent Diuretic and Natriuretic Properties. Flynn, T.G., de Bold, M.L., and de Bold, A.J. *Biochem. Biophys. Res. Commun.*, 117:859-865, 1983.
25. Natriuretic Effect of Atrial Extract on Isolated Perfused Kidney. Baines, A.D., de Bold, A.J., and Sonnenberg, H. *Can. J. Physiol. Pharmacol.*, 61:1462-1466, 1983.
26. Demonstration of Stellate Cells of the Pars Intermedia of the Pituitary Gland Using a New Silver Impregnation Technique. de Bold, M.L., de Bold, A.J. and Kraicer, J. *Stain Technol.*, 59:49-52, 1984.
27. Isolation and Nucleotide Sequence of a Cloned Cardionatrin cDNA. Kennedy, B.P., Marsden, J.J., Flynn, T.G., de Bold, A.J., and Davies, P.L. *Biochem. Biophys. Res. Commun.*, 122:1076-1082, 1984.
28. Alignment of Rat Cardionatrin Sequences with the cDNA Derived Sequence of Preprocardionatrin. Flynn, T.G., Davies, P.L., Kennedy, B.P., de Bold, M.L., and de Bold, A.J. *Science*, 228:323-325, 1985.
29. Immunocytochemical Demonstration of Cardionatrin in Human Atrial Myocardium. de Bold, M.L., and de Bold, A.J. In: *Immunocytochemistry in Tumour Diagnosis*, (Ed. J. Russo), Martinus Nijhoff Publishing, Boston, Mass., pp. 202-206, 1985.

30. Atrial Natriuretic Factor. de Bold, A.J. In: Nephrology Today. Proceedings of the IXth International Congress of Nephrology, Springer-Verlag, New York, pp.257-259, 1985.
31. Main Forms of Immunoreactive Cardionatrin in Atrial Extracts and in Atrial Specific Granules. Flynn, T.G., de Bold, A.J., de Bold, M.L., Davies, P.L., and Kennedy, B.P. Biochemical Society Transactions, 13:1141, 1985.
32. Atrial Natriuretic Factor. Historical Introduction and Overview. de Bold, A.J. In: Peptides: Structure and Function, (Eds. Deber, C.M., Hruby, V.J., and Kopple, K.D.), Proceedings of the Ninth Annual American Peptide Symposium, Toronto, Ontario, June 24- 28, pp. 909-915, 1985.
33. Atrial Natriuretic Factor: Polypeptide Hormone Produced by the Heart. de Bold, A.J. Science, 230:767-770, 1985.
34. Rapid Ventricular Pacing in the Dog: Pathophysiologic Studies of Heart Failure. Armstrong, P.W., Stopps, T.P., Ford, S.E., and de Bold, A.J. Circulation, 74:1075-1084, 1986.
35. Functional-Morphological Studies on In Vitro Cardionatrin Release. de Bold, A.J., de Bold, M.L., and Sarda, I.R. J. Hypertension, 4: S3-S7, 1986.
36. Morphological and Biochemical Aspects of Atrial Natriuretic Factor (Cardionatrin). de Bold, A.J., Davies, P.L., de Bold, M.L., Flynn, T.G., Kennedy, B.P., Marsden, J.J., Sarda, I.R., and Tadross, O. NAITO Foundation International Symposium on Natural Products and Biological Activities. Eds. H. Imura, T.Goto, T. Murachi and T. Nakajima), University of Tokyo Press, pp 325- 333, 1986.
37. Atrial Natriuretic Factor: An Overview. de Bold, A.J. Fed. Proc., 45:2081-2085, 1986.
38. Lack of Interaction Between Atrial Natriuretic Factor and Renal Organic Anion Transport System. Goldinger, J.M., Hong, R.B., Lee, S.H., de Bold, A.J., and Hong, S.K. Proc. Exp. Biol. Med., 182:358-363, 1986.
39. Atrial Natriuretic Factor and Renal Function During Head-Out Water Immersion in Conscious Dogs. Miki, K., Hajduczuk, G., Klocke, M.R., Krasney, J.A., Hong, S.K. and de Bold, A.J. Am. J. Physiol., 25:R1000-R1004, 1986.
40. Atrial Natriuretic Factor: A Hormone Produced by the Heart. de Bold, A.J. In: Biotechnology; The Renewable Frontier, (Ed. Koshland, D.E.) pp 217-224, 1986.
41. Nomenclature For Atrial Peptides Dzau, V.J., Baxter, J.D., Cantin, M., de Bold, A.J., Ganten, D., Gross, K., Husain, A., Inagami, T., Menard, N., Poole, S., Robertson, J.I.S., Tang, J., and Yamamoto, K. N. Engl. J. Med., 316:1278-1279, 1987.
42. Functional Morphology of the Endocrine Component of the Heart. de Bold, A.J. In: American Society of Hypertension Symposium Series, Biologically Active Atrial Peptides, (Eds. Brenner, B.M. and Laragh, J.H.), New York, Raven Press, 1:1-2, 1987.
43. Atrial Stretch-Secretion Coupling and Immunoreactive Cardionatrin (IRC) Release *In Vitro*:

- Effect of Ca^{2+} and EGTA. de Bold, M.L. and de Bold, A.J. In: American Society of Hypertension Symposium Series, Biologically Active Atrial Peptides, (Eds. Brenner, B.M. and Laragh, J.H.), New York, Raven Press, 1:173-175, 1987.
44. Relation Between Atrial Specific Granules and Cardionatrin Synthesis and Storage in the Rat. Tadross, O.E., Sarda, I.R., Davies, P.L. and de Bold, A.J. In: American Society of Hypertension Symposium Series Biologically Active Atrial Peptides, (Eds. Brenner, B.M. and Laragh, J.H.), New York, Raven Press, 1:158-162, 1987.
 45. Study on the Factors Affecting the Radioimmunoassay of Cardionatrin. Sarda, I.R. and de Bold, A.J. In: American Society of Hypertension Symposium Series, Biologically Active Atrial Peptides, (Eds. Brenner, B.M. and Laragh, J.H.), New York, Raven Press, 1:213-215, 1987.
 46. Effect of Head-Out Immersion on Plasma Atrial Natriuretic Factor in Man. Pendergast, D.R., de Bold, A.J., Pazik, M. and Hong, S.K. Proc. Soc. Exptl. Biol. Med., 184:429-435, 1987.
 47. Historical Perspectives of Atrial Specific Granules. de Bold, A.J. In: Atrial Hormones and Other Natriuretic Factors (Mulrow, P.J. and Schrier, R. Eds.) Clinical Physiology Series, American Physiological Series, pp 1-5, 1987.
 48. Factors Affecting the Release of Immunoreactive Cardionatrin (IRC) *In Vitro* From Human and Rat Atria. de Bold, A.J., de Bold, M.L., Taichman, G.C., Boyd, D.A. and Keon, W.J. The Second World Congress on Biologically Active Atrial Peptides, New York, N.Y., May 20-21, 1987.
 49. On the Shoulders of Giants: The Discovery of Atrial Natriuretic Factor. de Bold, A.J. Can. J. Physiol. Pharmacol., 65:2007-2020, 1987.
 50. Factors Affecting Cardionatrin Release. de Bold, A.J. and de Bold, M.L. In: Highlights On Endocrinology (Eds. Christiansen, C. & Riis, B.J.), Norhaven Bogtrykkeri A/S, Copenhagen, pp. 161-163, 1987.
 51. Natriuretic Factors in Normotensive and Hypertensive Pregnancies: Preliminary Study of Water Immersion in Preeclampsia. Gregoire, I., Fievet, P., Roth, D., El Esper, N., Favre, H., Westeel, P., de Bold, A., and Fournier, A. Am. J. Hypertension, 5: S83-S85, 1987.
 52. Atrial Natriuretic Factor. de Bold, A.J., de Bold, M.L. and Reuben, M.M. In: Proceedings of the Xth International Congress of Nephrology, (Ed. Davison, A.M.), London, England, 1: 109-122, 1988.
 53. Atrial Natriuretic Factor During Head-Out Immersion at Night. Miki, K., Shiraki, K., Sagawa, S., de Bold, A.J., and Hong, S.K. Am J. Physiol 254 (Integrative and Comp. Physiol. 23): R235-R241, 1988
 54. Atrial Natriuretic Factor in Pregnancy-Induced Hypertension and Preeclampsia: Increased Plasma Concentrations Possibly Explaining These Hypovolemic States with Paradoxical Hyporeninism. Fievet, P., Fournier, A., de Bold, A.J., El Esper, N., Gregoire, I,

- Westeel, P.F., Renaud, H. and Makurssi, R. *Am. J. Hypertension*, 1:16-21, 1988.
55. Oubain-Like Natriuretic Factor and Atrial Natriuretic Factor in Pregnancy. Fievet, P., Gregoire, I., Fournier, A. Roth, D., Siegenthaler, G., El Esper, N., Favre, H., and de Bold, A.J. *Kidney International*, 34: S89-S92, 1988.
56. Physiological Effects of Synthetic Atrial Natriuretic Factor in Normal Conscious Dogs. Moe, G.W., Forster, C., de Bold, A.J., Armstrong, P.W. *Clinical and Investigative Medicine*, 11: 417-424, 1988.
57. Alterations in Serum Sodium in Relation to Atrial Natriuretic Factor and Other Neuroendocrine Parameters in Experimental Pacing- Induced Heart Failure. Moe, G.W., Stopps, T.P., Angus, C., Forster, C., de Bold, A.J., and Armstrong, P.W. *J.Am.Coll.Cardiol.* 13: 173-179, 1989.
58. Effect of Manipulations of Ca^{2+} Environment on Atrial Natriuretic Factor Release. de Bold, M.L. and de Bold, A.J. *Am. J. Physiol.*, 256: H1588-H1594, 1989.
59. Effect of Rat Cardionatrin I (Rat ANF 99-126) on the Response of Toad Skin to Angiotensin II. Coviello, A., Soria, M.O., Proto, M.C., Berman, D.M., Gamundi, S.S., Alonso, C.E.I. and de Bold, A.J. *Can. J. Physiol. Pharmacol.*, 67: 362-365, 1989.
60. Optimization of Atrial Natriuretic Factor Radioimmunoassay. Sarda, I.R., de Bold, M.L., and de Bold, A.J. *Clin Biochem*, 22: 11-15, 1989.
61. Atrial Natriuretic Factor. de Bold, A.J., de Bold, M.L., and Reuben, M.M. In: *Prohormones, Hormones and their Fragments: Processing Biological Activity and Pharmacology*, ED: J. Martinez, Ellis Horwood Ltd., Chapter 11, 317-324, 1989.
62. Atrialer Natriuretischer Faktor (ANF) und Ouabain-Ersetzender Faktor (ODF) Bei Normotensiver und Hypertensiver Schwangerschaft. Fournier, A., Fievet, P., Gregoire, I, El Esper, N., Esteel, P., Lalau, J.D., Makdassi, R., Favre, H., and de Bold, A.J. *Nieren-und Hochdruckkrankheiten*, Jahrgang 18, Nr. 8/1989, S329-S334.
63. Sequential Study of the Plasmatic Atrial Natriuretic Factor and the Urinary Excretion of an Ouabain Displacing Factor and of Dopamine in Normotensive Pregnant Women before and after Labour. el Esper N., Gregoire I, Fievet P, Lalau J.D., Westeel P.F., Favre H., de Bold A.J., Fournier, A. *Archives Des Maladies Du Coeur Et Des Vaisseaux* 82: 1057, 1989.
64. Plasma Atrial Natriuretic Factor and Urinary excretion of a Ouabain Displacing Factor and Dopamine in Normotensive Pregnant Women before and after Delivery. Gregoire, I., el Esper N., Gondry, J., Boitte, F., Fievet, P., Makdassi, R., Westeel P.F., Lalau, J.D., Favre H., de Bold A.J. and Fournier, A. *Am. J. Obst. Gynecol.* 162:71, 1990.
65. Pharmacokinetics, Hemodynamic, Renal, and Neurohormonal effects of Atrial Natriuretic Factor in Experimental Heart Failure. Moe, G.W., Forster, C., de Bold, A.J., Armstrong, P.W. *Clinical & Investigative Medicine - Medicine Clinique Et Experimentale* 13: 111, 1990.
66. Pathophysiological Role of Changing Atrial Size and Pressure in Modulation of Atrial

- Natriuretic Factor during Evolving Experimental Heart Failure. Moe, G.W., Angus, C., Howard, R.J., de Bold, A.J., Armstrong, P.W. *Cardiovasc. Res.*24: 570, 1991.
67. Stretch Secretion Coupling in Atrial Cardiocytes: Dissociation Between ANF Release and Atrial Contractility. Kuroski-de Bold, M.L., de Bold, A.J. *Hypertension* 18: III-169-III-178, 1991.
68. A Decade of ANF Research. de Bold, A.J., de Bold, M.L., Boer P.H., Mangat, H., Dubé, G., Johnson, F. *Can. J. Physiol. Pharmacol.* 69: 1480-1485 1991.
69. Atrial Natriuretic Factor in Pregnancy and Pregnancy Induced Hypertension. Fournier, A., Gregoire, I., El Esper, N., Lalau, J.D., Westeel, P.F., Makdassi, R., Fievet, P., de Bold, A.J. *Can. J. Physiol. Pharmacol.*, 69:1601-1608, 1991.
70. Post-Transcriptional Processing of Atrial Natriuretic Factor by Adult Rat Atrial Cardiocytes in Culture. Dubé, G.R., Kuroski-de Bold, M.L. and de Bold, A. J. *Can. J. Physiol. Pharmacol.*, 69: 1480-1485, 1993.
71. Stretch-Induced Atrial Natriuretic Factor Release Utilises a Rapidly Depletable Pool of Newly Synthesised Hormone. Mangat, H. and de Bold, A.J. *Endocrinology* 133: 1398-1403, 1993.
72. Neuroendocrine Response to Cardiac Transplantation. Masters, R. G., Koshal, A., Davies, R.A., Keon, W.J. and de Bold, A.J. *Can. J. Cardiol.*, 9:609-617, 1993.
73. Atrial Natriuretic Factor in Experimental Acute Chagas' Disease. Piazza, L.A., de Bold, A.J., Santamarina, N., Hliba, E., Rudiolo, E.R. *Parasitol. Res.* 80: 78-80, 1994.
74. Epicardial Mesothelial Cells Synthesise and Release Endothelin Eid, H., Kuroski -de Bold, M.L., Chen, J.H. and de Bold, A.J. *J.Cardiovasc.Pharmacol.* 24: 715-720, 1994.
75. Selective Changes in Natriuretic Peptide and Early Response Gene Expression in Isolated Rat Atria Following Stretch Or Endothelin-1. Bruneau, B. and de Bold, A.J. *Cardiovasc. Res.* 28: 1519-1525, 1994.
76. Atrial natriuretic Factor Contributes to the Mineralocorticoid Escape Phenomenon: Evidence For A Guanylate Cyclase-Mediated Pathway. Yokota,N., Bruneau,B.G., Kuroski-de Bold, M.L. and de Bold,A.J. *J.Clin.Invest.* 94: 1938-1946, 1994.
77. Regulation of alpha-smooth actin expression in adult cardiomyocytes through a tyrosine kinase signal transduction pathway. Eid,H., Chen, J.H. and de Bold,A.J. *Ann.N.Y.Acad.Sci.*, 752: 192-201, 1995.
78. Dissociation of Cardiac Hypertrophy, Myosin Heavy Chain Isoform Expression, and Natriuretic Peptide Production in DOCA-salt Rats. Yokota,N., Bruneau,B.G., Fernandez,B.E., Kuroski-de Bold, M.L., Piazza,L.A., Eid,H. and de Bold,A.J. *Am.J.Hyperten.*8: 301-310, 1995.
79. α_1 -Adrenergic Stimulation of Isolated Rat Atria Results in Discoordinate Increases in Natriuretic Peptide Secretion and Gene Expression, and Enhances *Egr-1* and *c-myc* Expression. Bruneau B.G., Piazza L. A, and de Bold A. J. *Endocrinology* 137: 137-143, 1996.

80. Effects of Renal Neutral Endopeptidase Inhibition on Sodium Excretion, Renal Hemodynamic and Neurohormonal Activation in Patients with Congestive Heart Failure.. Kimmelstein, C.D., Perrone, R., Kilcoyne, L., Souhrada, J., Udelson, J., Smith, J., de Bold, A.J., Griffith, J. and Konstam, M.A. *Cardiology* 87: 46-53, 1996.
81. Mechanical and Neuroendocrine Regulation of the Endocrine Heart de Bold, A.J., Bruneau, B.G. and Kuroski de Bold, M.L. *Cardiovasc. Res.* 31:7-18, 1996.
82. Evidence for Load-dependent and Load-independent Determinants of Cardiac Natriuretic Peptide Production. Ogawa, T., Linz, W., Stevenson, M., Bruneau, B.G., Kuroski de Bold, M.L., Chen, J.H., Eid, H., Schölkens, B.A. and de Bold, A.J. *Circulation* 93: 2059-2067, 1996.
83. Mechanical and Receptor-Mediated Modulation of Endocrine Function in Isolated Rat Atria. Selective Enhancement of Brain Natriuretic Peptide Gene Expression. Bruneau, B.G., Piazza, L.A., and de Bold, A.J. *Am J Physiol.* 273: H2678-H2686, 1997.
84. Tissue Specific Regulation of Renal and Cardiac Atrial Natriuretic Factor Gene Expression in DOCA-Salt Rats. Ogawa, T., Bruneau, B.G., Yokota, N., Kuroski de Bold, M.L., and de Bold, A.J. *Hypertension* 30: 1342-1347, 1997.
85. Regulation of Aortic Atrial Natriuretic Factor and Angiotensinogen in Experimental Hypertension. Tsuneo Ogawa, Wolfgang Linz, Bernward A. Schölkens, Adolfo J. de Bold *Cardiovasc. Pharmacol.*, 32: 1001-1008, 1998.
86. Variable Renal Atrial Natriuretic Factor Gene Expression in Experimental Hypertension Tsuneo Ogawa, Wolfgang Linz, Bernward A. Schölkens, Adolfo J. de Bold *Hypertension*, 33:1342-7, 1998.
87. Characterization of Natriuretic Peptide Production By Adult Heart Atria Tsuneo Ogawa, Marcelo Vatta, Adolfo J. de Bold. *Am. J. Physiol.*, 276:H1977-86, 1999.
88. Discoordinate Modulation of Natriuretic Peptides During Acute Cardiac Allograft Rejection In Humans. Masters, R.G., Davies R., Veinot, J.P., Hendry, P.J., Smith, S.J., de Bold, A.J. *Circulation*, 100: 287-91, 1999.
89. Natriuretic Peptides. de Bold, A.J. and Bruneau, B.G. Invited Chapter. *Handbook of Physiology, Section 7, The Endocrine System. Volume III: Endocrine Regulation of Water and Electrolyte Balance.* John C.S. Fray, Volume Editor, H. Maurice Goodman, Section Editor. pp 377-409, 2000.
90. Effect Of Selective E_{t_A} Receptor Blockade On Natriuretic Peptide Gene Expression In Doca-Salt Hypertension. Bianciotti, Liliana G. and de Bold, Adolfo J. *Am J Physiol Heart.* 279: H93-H101 2000.
91. Modulation Of Cardiac Natriuretic Peptide Gene Expression Following Endothelin Type A Receptor Blockade In Renovascular Hypertension. Bianciotti, Liliana G. and de Bold, Adolfo

- J. Circulation Research, 49: 808-816, 2001.
92. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Reprinted from *Life Sci.* 28:89-94, 1981. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. *J Am Soc Nephrol.* Feb;12(2):403-9, 2001.
93. The Atrial Natriuretic Factor Family of Polypeptide Hormones de Bold, A J. Invited entry for *The Encyclopedia of Molecular Medicine*, Thomas E. Creighton, Editor. John Wiley & Sons, Inc., New York, NY. 2001.
94. Cardiomyopathy in *Irx4*-deficient mice is preceded by abnormal ventricular gene expression. Bruneau BG, Bao ZZ, Fatkin D, Xavier-Neto J, Georgakopoulos D, Maguire CT, Berul CI, Kass DA, Kuroski-de Bold ML, de Bold AJ, Conner DA, Rosenthal N, Cepko CL, Seidman CE, Seidman JG. *Mol Cell Biol* 21:1730-6, 2001.
95. The Physiological and Pathophysiological Modulation of the Endocrine Function of the Heart. de Bold AJ, Ma KK-Y, Zhang Y, M. Kuroski de Bold ML, Bensimon M, Khoshbaten A. *Can.J.Physiol.Pharmacol.*70: 705-714, 2001.
96. Atrial Natriuretic Factor Gene Expression In Doca-Salt Hypertension Following Blockade Of The Type B Endothelin Receptor. Bianciotti, LG and de Bold AJ. *Am.J.Physiol.* 282: H1127-H1134, 2002
97. Gene Expression of Natriuretic Peptides (NPs) and Their Receptors (NPRs) In Human Coronary Arteries. Casco VH , Veinot JP, Kuroski de Bold ML, Masters RG, Stevenson MA and de Bold AJ. *J. Histochem. Cytochem.* 50: 799, 2002.
98. Discoordinate re-expression of cardiac fetal genes in N(omega)-nitro-L-arginine methyl ester (L-NAME) hypertension. Zhang, Y, Carreras, D and de Bold, AJ. *Cardiovasc Res.* 571:158-67, 2003.
99. Brain Natriuretic Peptide Gene Expression and Secretion is Selectively Up-Regulate by Pro-inflammatory Cytokines IL-1 β , TNF- α and Conditioned Medium Derived from Mixed Lymphocyte Reactions. Ma, K K-Y and de Bold, AJ. *J. Cell Molec.Cardiol.* 36: 505-513, 2004.
100. B-Type Natriuretic Peptide Predicts Successful Cardioversion in Patients with Atrial Fibrillation and Maintenance of Sinus Rhythm. Beck-da-Silva L, de Bold AJ, Fraser M, Williams K, Struthers C, Davies R and Haddad H. *Can.J.Cardiol.* 20: 1245-1248, 2004
101. Participation of G Proteins in Natriuretic Peptide Hormone Secretion from Heart Atria. Bensimon M. Chang AI, Kuroski de Bold, ML, Ponce A, Carreras D and de Bold AJ. *Endocrinology* 145: 5313-5321, 2004
102. Effect of Bisoprolol on Right Ventricular Function and Brain Natriuretic Peptide in Patients with Heart Failure. Beck-da-Silva L, de Bold, AJ, Davies, RA, Chow BJW, Ruddy, TD, Fraser, M, Struthers C and Haddad H. *Cong.Heart Fail.J.* 10: 127-132, 2004.

103. Brain Natriuretic Peptide as a Guide to Beta-Adrenergic Blocker Titration in Patients with Heart Failure. Beck-da-Silva L, de Bold AJ, Davies RA, Chow BJW, Ruddy TD, Fraser M, Williams, K, Struthers C and Haddad H. *Congestive Heart Failure* 11:248-253, 2005.
104. Determinants of Inducible Brain Natriuretic Peptide Promoter Activity Ma, K. K., Banas, K. and de Bold, A.J. *Regulatory Peptides* 128: 169– 176, 2005.
105. Determinants of natriuretic peptide gene expression. McGrath MF and de Bold A *Peptides* 26:933-943,2005.
106. Neuroendocrine Profiling of Humans Receiving Cardiac Allografts. Ogawa T, Veinot JP, Davies RA, Haddad H, Smith SJ, Masters, RG, Hendry PJ, Starling, R, Kuroski de Bold, ML, Ponce A, Ma KK, Williams K, de Bold AJ. *J. Heart Lung Transp.* 24: 1046-1054, 2005.
107. The endocrine function of the heart. McGrath MF, Kuroski de Bold ML and de Bold AJ. *Trends Endocrinol Metab.* 16:469-77, 2005.
108. Determinants of natriuretic peptide production by the heart: basic and clinical implications. de Bold, AJ and de Bold, ML. *J Investig Med* 53:371-7, 2005.
109. Gene Expression, Processing and Secretion of Natriuretic Peptides. Physiological and Diagnostic Implications. Ramos H and de Bold AJ. *Clinics of North America, Heart Failure Clinics* 2 (3): 255, 2006.
110. Determinants of Brain Natriuretic Peptide (BNP) Gene Expression and Secretion in Acute Cardiac Allograft Rejection. de Bold AJ. *Current Opinions in Cardiology* 22: 146-150, 2007.
111. Relationship between Natriuretic Peptides and Inflammation. Proteomic Evidence Obtained during Acute Cardiac Allograft Rejection in Humans. Meirovich Y F, Veinot JP, Kuroski de Bold ML, Haddad H, Davies RA, Masters RG, Hendry PJ and de Bold AJ. *J.Heart Lung Transplant.* 27:31-7. 2008.
112. Angiotensin II Receptor Antagonism Reverts Cardiac BNP Upregulation and Secretion Observed in Myocarditis. Ogawa T, Veinot, JP, Georgalis T and de Bold AJ *Am.J.Physiol.* 294: H5296, 2008.
113. Cardiac Natriuretic Peptides Gene Expression and Secretion in Inflammation de Bold AJ. *Invest. Med.* 57: 29-32, 2009.
114. Role of potassium channels in stretch-promoted atrial natriuretic factor (ANF) secretion Ogawa T., Forero M, Burgon PG, Kuroski de Bold ML, Georgalis T and de Bold AJ *J.Am.Soc.Hyperten.* 3: 9-18, 2009.
115. Transcriptional Analysis of the Heart with Special Reference to its Endocrine Function. McGrath MF and de Bold, AJ. *BMC Genomics* 10:254, 2009.
116. Invited Editorial: Cardiac natriuretic peptides: gaining further insights into structure-function relationships. de Bold, AJ. *J Am Coll Cardiol.* 54:1033, 2009.

117. The Cardiac Hormones ANF and BNP Modulate Proliferation in the Unidirectional Mixed Lymphocyte Reaction. Kuroski de Bold ML, Etchepare A, Martinuk A and de Bold AJ *J Heart Lung Transplant* 29(3):323-6, 2010.
118. Thirty years of research on atrial natriuretic factor: historical background and emerging concepts. de Bold AJ. *Can J Physiol Pharmacol.* 89: 527-31, 2011.
119. Characterization of a Long-Acting Recombinant Human Serum Albumin- Atrial Natriuretic Factor Fusion Protein. Kuroski de Bold ML ,Sheffield WP, Martinuk A and de Bold AJ. *Regul Pept* 10; 175:7-10, 2012.
120. Dexamethasone-Induced Ras Protein 1 (RASD1) as a Modulator of Hormone Gene Expression and Secretion in the Volume Overload Heart. McGrath MF, Ogawa T, and de Bold AJ *Am J Physiol Heart Circ Physiol.* 302(9): H1826-37, 2012
121. Uncoordinated regulation of atrial natriuretic factor and brain natriuretic peptide in lipopolysaccharide-treated Rats. Ogawa T, de Bold AJ. *Biomarkers.* 2012 Mar;17(2):140-9.
122. Brain natriuretic Peptide production and secretion in inflammation. Ogawa T, de Bold AJ. *J Transplant.* Vol. 2012; Article ID 9623472012, 2012.
123. Phospholipase C signaling tonically represses basal atrial natriuretic factor secretion from atria of the heart. Chang AI, Forero McGrath M, de Bold AJ. *Am J Physiol Heart Circ Physiol.* 304(10):H1328-36, 2013.
124. The endocrine heart and inflammation. Ogawa T and de Bold AJ. *Medicina* 73: 562-6, 2013.
125. Natriuretic peptides in non-cardiac diseases. de Bold AJ. *Medicina (B Aires)* 74:266, 2014.
126. The heart as an endocrine organ. Ogawa T, de Bold AJ. *Endocr Connect.* 2014 Apr 15;3(2):R31-44.
127. Go protein subunit $Go\alpha$ and the secretory process of the natriuretic peptide hormones ANF and BNP. Roeske C, Martinuk A, Choudhry A, Hendy GN, Gollob M, Li Q, Georgalis T, de Bold AJ. *J Mol Endocrinol.* 54(3):277-88, 2015.
128. INTERACTING DISCIPLINES: Cardiac natriuretic peptides and obesity: perspectives from an endocrinologist and a cardiologist. Ramos HR, Birkenfeld AL, de Bold AJ. *Endocr Connect.* 4:R25-36, 2015.

ABSTRACTS

1. Morphological and Functional Studies on the Cell of the Embryonal Pancreas in the Rabbit. de Bold, A.J., Bencosme, S.A., Wilson, M.B., Aleyassine, H., and de Bold, M.L. *Anat. Rec.*, 166:296, 1970.

2. Pancreatic Islet Cell Tumour Associated with Hyperinsulinism. Diagnostic Problems. Bencosme, S.A., Wilson, M.B., Aleyassine, H., de Bold, A.J., and de Bold, M.L. Annual Congress Quebec Association Lab. Physicians, 1971.
3. Norepinephrine Distribution During a Fractionation Procedure to Isolate Specific Granules from Atrial Homogenates. de Bold, A.J., and Bencosme, S.A. J. Cell Biol., 55:58a, 1972.
4. An Improved Method for Total Body Fixation by Intravascular Perfusion. de Bold, M.L., Feria-Velasco, A., Bencosme, S.A., and de Bold, A.J. Exptl. Biol. Med., (Champlain Section), May 1973.
5. Vascular Perfusion Fixation for Electron Microscopy: An Improved Method. de Bold, M.L., Feria-Velasco, A., Bencosme, S.A., and de Bold, A.J. Lab. Invest., 28: 382, 1973.
6. Subcellular Distribution of Endogenous Epinephrine and Norepinephrine in the Rat Atrium. de Bold, A.J., and Bencosme, S.A. Lab. Invest., 28: 382, 1973.
7. Autoradiographic Analysis of Label Distribution in Mammalian Atrial and Ventricular Cardiocytes After Exposure to Tritiated Leucine. de Bold, A.J., and Bencosme, S.A. Seventh Annual Meeting of the International Study Group for Research in Cardiac Metabolism, Quebec City, 1974.
8. Selective Demonstration of Specific Atrial Granules at the Light Microscopic Level. De Bold, A.J., and Bencosme, S.A. Lab. Invest., 32:6, 1975.
9. Histological and Autoradiographic Investigations on the Specific Granulation of the Atrial Myocardium. de Bold, A.J. Fed. Proc., 34:826, 1975.
10. Demonstration of Tryptaminergic Mechanism in the Rat Cell. Pulido, O.M., de Bold, A.J., de Bold, M.L., and Bencosme, S.A. Soc. Exptl. Biol. Med. (Champlain Section), May 1976.
11. Intracellular-Cell Serotonin and the Dynamics of Insulin Release. Pulido, O.M., Bencosme, S.A., de Bold, M.L., and de Bold, A.J. Lab. Invest., 36:348, 1977.
12. Morphometry of Atrial Granulation. Effect of Age. de Bold, A.J. J. Molec. Cell Cardio., 9:21, 1977.
13. Effect of Water, Sodium Restriction and Desoxycorticosterone on Granularity of HearAtrial Muscle Cells. de Bold, A.J. Proc. Can. Fed. Biol. Soc., 21:139, 1978.
14. Renin-Like Activity in Rat Heart Atria. Rojo-Ortega, J.M., de Bold, A.J., and Bencosme, S.A. J. Molec. Cell Cardio., 11(Supp. 1):52, 1979.
15. Extracellular Space of the Pars Intermedia (PI) of the Rat Adenohypophysis as Revealed by Ruthenium Red (RR). de Bold, A.J., Kuroski de Bold, M.L. and Kraicer, J. Ann. R. Coll. Phys. Surg. (Canada), 12:41, 1979.

16. Pars Intermedia (PI) of the Rat Adenohypophysis: Its Extracellular Space as Revealed by Horseradish Peroxidase (HRP). de Bold, A.J., Kuroski de Bold, M.L. and Kraicer, J. Fed. Proc., 38:979, 1979.
17. Pyruvate Kinase Levels in the Lymphocytes of Anergic Malnourished Patients. Wren, S.F., and de Bold, A.J. Presented to the Association for Academic Surgery Meeting, New Jersey, November 1979.
18. The Effect of Total Parenteral Nutrition (TPN) on the Kinetics of Intralymphocytic Pyruvate Kinase. Wren, S.F., and de Bold, A.J. Presented at the Am. Soc. Parenteral and Enteral Nutrition, Chicago, January 1980.
19. The Effect of Delayed Hypersensitivity Skin Testing on the Kinetics of Intralymphocytic Pyruvate Kinase in Humans. Wren, S.F.G., and de Bold, A.J. Proc. Can. Fed. Biol. Soc., 23:82, 1980.
20. Rapid and Potent Natriuretic Response to Intravenous Injection of Atrial Myocardial Extract in Rats. de Bold, A.J., Borenstein, H.B., Veress, A.T., and Sonnenberg, H. Clin. Res., 28:658A, 1980.
21. Demonstration of Stellate-Shaped Cells in the Pars Intermedia (PI) of the Rat Hypophysis. de Bold, A.J., de Bold, M.L., Ludwin, S.K., and Kraicer, J. Clin. Res., 28:669A, 1980.
22. The Effect of Rapid Weight Loss (Jejeuno-Ileal Bypass-JIB) on the Kinetics of Intralymphocytic Pyruvate Kinase (PK) and Delayed Hypersensitivity Skin Testing. Wren, S.F., and de Bold, A.J. Clin. Res., 28:689A, 1980.
23. Rapid and Potent Natriuretic Response to Intravenous Injection of Atrial Myocardium. Extract in Rats. Sonnenberg, H., Veress, A.T., Borenstein, H.B., and de Bold, A.J. The Physiologist, 23:71, 1980.
24. Intrarenal Localisation of the Natriuretic Effect of Cardiac Atrial Extract. Sonnenberg, H., Cupples, W.A., de Bold, A.J., and Veress, A.T. Proc. N.Y. Acad. Sci., 1981 (NYAS Conference on Hormonal Regulation of Epithelial Transport. November 10-12, 1980).
25. Myocardial Glycolytic Enzyme Activity during Cardiopulmonary Bypass in Humans. Salerno, T.G., de Bold, A.J., and Wren, S.F.G. Can. J. Surg., 24:604, 1981.
26. Effect of Cardiac Atrial Extract on Segmental Nephron Transport in the Rat Kidney. Cupples, W.A., Veress, A.T., de Bold, A.J., and Sonnenberg, H. Proc. Fed. Am. Soc. Exptl. Biol., 40:554, 1981.
27. Natriuretic Factor (NF) of the Rat Heart Atria. Studies on Isolation and Properties. de Bold, A.J. Proc. Fed. Am. Soc. Exptl. Biol., 40:554, 1981.
28. Natriuretic Factor (NF) of the Rat Heart Atria. Studies on Isolation and Properties. de Bold, A.J. Proc. Can. Fed. Biol. Soc., 24:161, 1981.

29. Ultrastructure of the Innervation of the Pars Intermedia (PI) of the Rat Pituitary after Administration of 5-Hydroxydopamine. de Bold, M.L., de Bold, A.J., and Kraicer, J. Proc. Can. Fed. Biol. Soc., 24:231, 1981.
30. Demonstration and Microanatomical Distribution of Stellate Cells of the Pars Intermedia (PI) of the Rat Pituitary Using a Novel Silver Impregnation Technique. de Bold, M.L., de Bold, A.J., and Kraicer J. Proc. Microscop. Soc. Can., 8:80-81, 1981.
31. The Relationship Between Atrial Natriuretic Factor and Specific Atrial Granules. de Bold, A.J. Proc. Fed. Am. Soc. Exptl. Biol., 41:990, 1982.
32. Cardionatrin I. A Potent Diuretic and Natriuretic Peptide Isolated from the Heart Atria. de Bold, A.J., and Flynn, T.G. Proc. Fed. Am. Soc. Exptl. Biol., 42:611, 1983.
33. Purification and Characterization of Rat Atrial Cardionatrin - Potential Diuretic, Natriuretic and Vasoactive Hormones. Flynn, T.G., de Bold, M.L. and de Bold, A.J. Proceedings of the 7th International Congress of Endocrinology. Excerpta Medica International Congress Series 652. Elsevier Science Publishing Co. Inc., New York, N.Y., pp 873, 1984.
34. Morphological and Biochemical Aspects of Atrial Natriuretic Factor (Cardionatrin). de Bold, A.J. Proceedings of the Naito Foundation International Symposium on Natural Products and Biological Activities, Keidanren, Kaikan, Japan, November 5-7, 1984 .
35. Atrial Natriuretic Factor: An Overview. de Bold, A.J. Proceedings of the 17th Annual meeting of the American Society of Nephrology, Washington D.C., December 9-12, 1984.
36. Main Forms of Immunoreactive Natriuretic Factor in Atrial Tissue and in Isolated Specific Atrial Granules. Davies, P.L., de Bold, A.J., de Bold, M.L., Flynn, T.G. and Kennedy, B.P. Can. Fed. Biol. Societies, Toronto, Ontario, June 17-21, 1985.
37. Main Forms of Immunoreactive Natriuretic Factor in Atrial Tissue and in Isolated Specific Atrial Granules. Flynn, T.G., de Bold, A.J., de Bold, M.L., Davies, P.L. and Kennedy, B.P. Biochemical Society meeting, Cardiff, Wales, March 20-22, 1985.
38. Atrial Stretch-Secretion Coupling and Immunoreactive Cardionatrin (IRC) Release *In Vitro*: Effect of Ca^{2+} and EGTA. de Bold, M.L. and de Bold, A.J. The First World Congress on Biologically Active Atrial Peptides, New York, N.Y., May 29- June 1, 1986.
39. Relation Between Atrial Specific Granules and Cardionatrin Synthesis and Storage in the Rat. Tadross, O.E., Sarda, I.R., Davies, P.L. and de Bold, A.J. The First World Congress on Biologically Active Atrial Peptides, New York, N.Y., May 29- June 1, 1986.
40. A Study on the Factors Affecting the Radioimmunoassay (RIA) of Cardionatrin (C). Sarda, I.R. and de Bold, A.J. The First World Congress on Biologically Active Atrial Peptides, New York, N.Y., May 29- June 1, 1986.
41. An Overview of Atrial Natriuretic Factor. de Bold, A.J. XXX International Congress of

Physiological Sciences, Vancouver, B.C., July 13-18, 1986.

42. Factors Affecting the Release of Immunoreactive Cardionatrin (IRC) *In Vitro* from Human and Rat Atria. de Bold, A.J., de Bold, M.L., Taichman, G.C., Boyd, D.A. and Keon, W.J. The American Society of Hypertension World Congress on Biologically Active Atrial Peptides, New York, N.Y., May 17-21, 1987.
43. Factors Affecting Cardionatrin Release. de Bold, A.J. and de Bold, M.L. First European Congress of Endocrinology, Copenhagen, Denmark, June 21-25, 1987.
44. Ouabain Like Natriuretic Factor (OLNF) and Atrial Natriuretic Factor (ANF) in Normal Pregnancy, in Pregnancy Induced Hypertension (PIH) and in Preeclampsia (PE). Fievet, P., Fournier, A., Favre H., Roth O., Siegenthaler, G., Gregoire, I., El Esper, N., and de Bold, A.J. Xth International Congress of Nephrology, London, England, July 26-31, 1987.
45. Hemodynamic and Renal Effects of Atrial Natriuretic Factor are Attenuated in Experimental Heart Failure. Moe, G.W., Forster, C., de Bold, A.J. and Armstrong, P.W. Canadian Cardiovascular Society Annual Meeting, Edmonton, Alberta, October 28-31, 1987.
46. Pathophysiologic Role of Atrial Size and Pressure in the Modulation of Plasma Natriuretic Factor During Evolving Experimental Heart Failure. Moe, G.W., Howard, R.J., Angus, C., de Bold, A.J. and Armstrong, P.W. Canadian Cardiovascular Society Annual Meeting, Edmonton, Alberta, October 28-31, 1987.
47. Functional Morphology of ANF Release. de Bold, A.J. and de Bold, M.L. UCLA Symposium: Biological and Molecular Aspects of Atrial Factors, Steamboat Springs, Colorado, January 17-23, 1988.
48. Sequential Study of Plasma Atrial Natriuretic Factor (P. ANF), Urinary Oubain-Like Natriuretic Factor (U. OLNf) and Urinary Dopamine in Normotensive Pregnant Women Before and After Delivery. Gregoire, I., El Esper, N., Fournier, A., Fievet, P., Westeel, P.F., de Bold, A.J., and Favre, H. International Congress of the International Society for the Study of Hypertension in Pregnancy, Montreal, Quebec, 1988.
49. Effects of Divalent Cations and Lanthanum on Immunoreactive Cardionatrin (IRC; ANF 99-126) Research. de Bold, M.L., and de Bold, A.J. FASEB J., 2:65, 1988.
50. Studies on Stretch - Secretion Coupling and Other Cell Properties of Atrial Cardiocytes. de Bold, A.J., and de Bold, M.L. Kyoto Symposium on ANP, Kyoto, Japan, July 15-23, 1988.
51. Atrial Natriuretic Factor: A Marker of Right Ventricular Failure During Acute Pressure Overload? VizeL, S., de Bold, A.J. and Calvin, J.E. Canadian Cardiovascular Society - Annual Meeting, October 26-29, 1988.
52. Atrial Natriuretic Factor: A Marker of Right Ventricular Failure During Acute Pressure Overload? VizeL, S., de Bold, A.J. and Calvin, J.E. American Heart Association - 61st Scientific Sessions, November 14-17, 1988.

53. Atrial Natriuretic Factor: A Marker of Right Ventricular Failure During Acute Pressure Overload? Calvin, J.E., de Bold, A.J., and Vizek, S. American College of Cardiology - 38th Annual Scientific Session, March 19-23, 1989.
54. The Effect of Catecholamines and Neurotransmitters on ANF Release. de Bold, M.L., and de Bold, A.J. 73rd Annual Meeting Federation of American Societies for Experimental Biology, New Orleans, Louisiana, March 19-23, 1989.
55. A Decade of ANF Research - Keynote Address de Bold, A.J. Ottawa Symposium on Atrial Natriuretic Factor, "A Decade of ANF Research" International Hypertension Society Satellite Symposium, Ottawa, June 21-23, 1990
56. Plasma Concentrations of Endothelin and Atrial Natriuretic Peptide in Normal and Hypertensive Pregnancy. Westeel, P.F., Lalau, J.D., El Esper, N., Achard, J.M., Gregoire, I., Fievet, P., de Bold, A.J., and Fournier, A. 23rd Annual Meeting The American Society of Nephrology, Ottawa, Ontario, December 2- 5, 1990
57. Different Gene Activation Mode for Atrial Natriuretic Factor versus Structural Heart Muscle Gene. Boer, P.H., Kuroski-de Bold, M.L., de Bold, A.J., Ottawa Symposium on Atrial Natriuretic Factor, "A Decade of ANF Research" International Hypertension Society Satellite Symposium, Ottawa, June 21-23, 1990
58. Effect of Angiotensin II, Phorbol Ester and Potassium Depolarization on ANF Release Kuroski-de Bold, M.L., de Bold, A.J., Ottawa Symposium on Atrial Natriuretic Factor, "A Decade of ANF Release" International Hypertension Society Satellite Symposium, Ottawa, June 21-23, 1990, p 14
59. Endothelin (ET) - Induced Atrial Natriuretic Factor (ANF) Release: Modulation by Calcium de Bold, A.J., and Kuroski-de Bold, M.L., FASEB J. Part I: A289, 1990
60. Studies on Basal and Stretch-Induced Atrial Natriuretic Factor (ANF) Release Kuroski-de Bold, M.L., de Bold, A.J., FASEB J. Part I: A289, 1990
61. Presence of Stretch-Activated Channels in Freshly Isolated Adult Rat Heart Cells. Bustamante, J.O., de Bold M.L., Boer P.H., and de Bold A.J. J Cell Biochem Suppl 15C:167, 1991
62. Different Gene Activation Mode for Atrial Natriuretic Factor *versus* Structural Heart Muscle Genes. P.H. Boer, M.L. de Bold, and A.J. de Bold. J Cell Biochem Suppl 15C: 160, 1991
63. Studies on ANF Processing and Release from Adult Rat Cardiocytes on Microcarrier Beads. G.R. Dubé, M.L. Kuroski-de Bold, A.J. de Bold. FASEB J Pt. II:A1021, 1991
64. Activation Mode of the Atrial Natriuretic Factor Gene During P₁₉ Cardiac Myogenesis. Boer, P.H., de Bold, M.L., de Bold, A.J., Bustamante, J.O. FASEB J Pt. II:A1748, 1991
65. Natriuretic Peptide storage and Release by Atrial Cardiomyocytes Kuroski-de Bold, M.L. and de Bold, A.J. Proc. 1991 USCD Asilomar Conference "Molecular and Cellular Biology

of the Cardiac Myocyte"

66. Activation of Atrial Natriuretic Factor Genes Types -A and -B but not -C during P-19 Cardiac Muscle Differentiation. Boer, P.H. and de Bold, A.J. Proc. 1991 USCD Asilomar Conference "Molecular and Cellular Biology of the Cardiac Myocyte"
67. Plasma Concentrations of Endothelin and Atrial Natriuretic Peptide in Normal and Hypertensive Pregnancy. Westeel P.F., Lalau J.D., El Esper N., Achard J.M., Gregoire I., Fievet P., de Bold A., Fournier A. Ottawa Symposium on Atrial Natriuretic Factor, "A Decade of ANF Research" International Hypertension Society Satellite Symposium, Ottawa, June 21-23, 1990
68. Endothelin and Atrial Natriuretic Factor Levels Vary with CHF Severity. E.R. O'Brien, T.D. Ruddy, R.A. Sochowski, S.A. Kearns, A.J. de Bold Can. J. Cardiol 1.7: 104A, 1991
69. Relationship of Endothelin to Symptoms and Hemodynamics in Congestive Heart Failure O'Brien, Ruddy, T.D., Sochowski, R.A., Kearns, S.A., de Bold, A.J. J. Am. Coll. Cardiol. 17: A, 1991
70. Effect of Renal Endopeptidase Inhibition on Sodium Excretion and Renal Hemodynamics in Heart Failure. C.D. Kimmelstiel, R.D. Perrone, L. Kilcoyne, J. E. Udelson, J. J. Smith, A. J. de Bold, E. Henry, J. F. Souhrada, M. A. Konstam. Am. Coll. Cardiol. 19: 146A, 1992
71. Endothelin Levels Following PTCA of the Left Anterior Descending Coronary Artery. M.Labinaz, T.D. Ruddy, J.F. Marquis, S.A. Kearns, M.R. LeMay, L.A. Higginson, B.P. Moran, A.J. de Bold Can. J. Cardiol. 8:109B, 1992
72. Morphological and Biochemical Studies on The Subcellular Distribution of A- and B- Type Natriuretic Factors in the Rat Heart. M. Kuroski-de Bold, O. Pulido, G. Dubé, B. Fernandez, and A.J. de Bold Faseb J. Pt. I:A1234, 1992
73. The Release of Newly Synthesised and Stored ANF under Basal and Stimulated Conditions Mangat, H. and de Bold, A.J. FASEB J. 7: A670, 1993
74. Temporal Pattern of Expression of Myosin Heavy Chain, ANF and BNF in Monoculture and Co-Culture of Adult Rat Ventricular Myocytes with Epicardial Mesothelial Cells. Eid, H., Chen, J.H., Kuroski-de Bold, M.L. and de Bold, A.J. J.Cell Biochem. Supp. 17D: 210, 1993
75. Effects of HS-142-1 (HS), an Antagonist of Natriuretic Peptide (NP) Bioactive Receptors, on Deoxycorticosterone Acetate (DOCA) Escape. Yokota, N., Kuroski-de Bold, M.L., and de Bold, A.J. J.Am.Soc.Nephrol. 4: 450, 1993
76. Transcriptional and Post-Translational Regulation of Atrial Natriuretic Factor (ANF) and Brain Natriuretic Peptide (BNP) During the Development of DOCA-Salt Hypertension Yokota, N., de Bold, M. L. and de Bold, A.J. Circulation 88:I-315, 1993

77. Natriuretic Peptide and Early Response Gene Expression in Isolated Rat Atria Following Stimulation by Stretch or Endothelin-1. Bruneau, B. and de Bold, A.J. *Am.J.Hypertens.* 7 (4, ptII): 79A, 1994
78. Regulation of Alpha-Smooth Muscle Actin Expression in Adult Cardiomyocytes Through A Tyrosine Kinase Signal Transduction Pathway. Eid, H., Chen, J.H. and de Bold,A.J. *Proceedings of the International Workshop on Myocardial Growth and Regeneration. NATO Advanced Research Workshop. Viterbo, Italy, 1994*
79. α_1 -Adrenergic Stimulation of Natriuretic Peptide Secretion and Gene Expression in Isolated Right atria. Bruneau, B.G., Piazza, L.A. and de Bold, A.J. *J.Molec.Cell .Cardiol.*, 27: A242, 1995
80. Natriuretic Peptide Production in Hypertensive rats With or Without Cardiac Hypertrophy Ogawa, T., Linz, W., Stevenson, M., Bruneau, B.G., Kuroski-de Bold, M.L. and de Bold, A.J. *J.Molec.Cell.Cardiol.* 27:A219, 1995
81. Natriuretic Peptide Production in Hypertensive rats With or Without Cardiac Hypertrophy Ogawa, T., Linz, W., Stevenson, M., Bruneau, B.G., Kuroski-de Bold, M.L. and de Bold, A.J. *Can.J.Cardiol.* 11: 128E, 1995.
82. Characterization of the Cardiac Conducting System in the Rat and Monkey (*Macaca fascicularis*) by Immunohistochemistry. Mueller, R., Pulido, O. Kuroski de Bold, M.L., Luus, L., Rowsell, P., Smyth, P., Langlois, I., de Bold, A.J. *FASEB J.* 9: A374, 1995
83. Regulation of Brain Natriuretic Peptide (BNP) in Male and Female Spontaneously Hypertensive Rats. Kuroski de Bold, M.L. and de Bold, A.J. *FASEB J.* 9:A78, 1995
84. Natriuretic peptide production in hypertensive rats with or without cardiac hypertrophy. Ogawa, T., Linz, W., Stevenson, M., Bruneau, B.G., Kuroski-de Bold, M.L. and de Bold, A.J. *Am. J. Hyperten.* 9: 8A, 1996
85. Specific Changes In Translational, Postranslational, Storage And Release Events Associated With Various Mechanical And Neuroendocrine Stimuli Of Cardiac Natriuretic (NP) Production. de Bold, A.J. *Proceedings of the 29th Assemblée Annuelle, Union des Sociétés Suisses de Biologie Expérimentale*, page A31, 1997.
86. Effect of Chronic Endothelin-1 (ET-1) Receptor (ET-1A) blockade on Natriuretic Peptide Gene Expression in Doca-Salt Hypertension". Bianciotti, L. and de Bold, A.J. *51th Annual Meeting of the Canadian Cardiovascular Society, Ottawa, October 23 1998.*
87. Physiological Roles of Natriuretic Peptides (NP) de Bold, A.J. *1st International Symposium of Cardiovascular Endocrinology and Metabolism. Kyoto, November 27-28, 1998*
88. Strategies on competing in science and technology de Bold, A.J. *1st Symposium on Teaching in Science and New Technologies. International Book Fair, Sponsorship by the Canadian Embassy in Buenos Aires, April 1999*

89. Natriuretic peptides: ubiquitous modulators of cardiovascular function and growth. de Bold, A.J. VI Meeting of the International Society for Heart Research. Latin American Section, and XVIII National Congress of Cardiology, Buenos Aires, May 1999.
90. Natriuretic peptides as cardiovascular sentries. Clinical use of plasma levels. de Bold, A.J. VI Meeting of the International Society for Heart Research. Latin American Section, and XVIII National Congress of Cardiology, Buenos Aires, May 1999.
91. Disruption of the Ventricle-Specific Homeobox Gene *Irx4* in Mice Leads to Cardiac Dysfunction and Hypertrophy. Bruneau, B.G., Bao, Z-Z, Fatkin, D., Georgakopoulos, D., Mudd, J.O., Conner, D.A., Schoen, F.J., de Bold, A.J., Cepko, C.L., Seidman, J.G. and Seidman C.E. *Circulation* 100 (Suppl 1), I347-348, 1999
92. Effect of Chronic Endothelin-1 (ET-1) Receptor (ET-1A) blockade on Natriuretic Peptide Gene Expression in Doca-Salt Hypertension. Bianciotti, L. and de Bold, A.J. *J.Molec.Cell.Cardiol.* 32:A34, 2000
93. Role of G_{i/o}-Protein Signalling in ANF Stretch-Secretion Coupling In Heart Atria. Bensimon, M.A. and de Bold, A.J. *J.Molec.Cell.Cardiol.* 33: A11, 2001
94. Pro-Inflammatory Cytokines Specifically Upregulate BNP Expression. Ma, K-Y and de Bold, A.J. *J.Molec.Cell.Cardiol.* 33: A70, 2001
95. Molecular basis for the altered secretion of the cardiac natriuretic peptides ANF and BNP during human acute cardiac allograft rejection. Ma, KK and de Bold, AJ. *Transplantation.* 27:S545, 2002
96. Expression and secretion of BNP is selectively upregulated by pro-inflammatory cytokines. Ma, K. K-Y., and de Bold, A.J. Abstract P2-589. Endocrine Society 85th Annual meeting. Philadelphia. USA. 2003.
97. Molecular Basis for the Altered Secretion of the Cardiac Natriuretic Peptides ANF and BNP During Human Acute Cardiac Allograft Rejection. Ma, K. K-Y., and de Bold A.J. *Transplantation* 27;74(4):545, 2003
98. Brain Natriuretic Peptide (BNP) as a Guideline to β -Blocker Titration in Patients with Heart Failure. Luis Beck da Silva, Adolfo de Bold, Margaret Fraser, Kathryn Williams, Christine Struthers, Haissam Haddad, Heart Failure Society of America Proceedings, S101, #377, 2003
99. Phospholipase C inhibitors increase atrial natriuretic factor secretion. Chang AI, de Bold AJ. *FASEB J. Part II:A1246*, 2004
100. Cardiac Hormones and Inflammation. de Bold, A.J. Proceedings of the 16th World Congress of Cardiothoracic Surgeons, Ottawa, Ontario. August 16-18, 2006
101. Inflammation and the endocrine Heart. de Bold, A.J. Proceedings of the Fifth Oulu Symposium on "Advances in Molecular and Cellular Biology of Vasoactive Factors"

Finland, September 9, 2006

102. Protein-Protein Interactions between an Atrial-Specific Go Protein and Secretory Products in the Vectorial Transport and Secretion of Natriuretic Peptides. de Bold, A.J., Ogawa T., Forero, M., Burgon, P., de Bold, M.L., Georgalis, T. Proceedings of the International Congress on Vasoactive Peptides. Ouro Preto, MG, Brazil, February 2008
103. Cardiac Natriuretic Peptides Gene Expression and Secretion in Inflammation. de Bold, A.J. Cardiac hormones: For the Treatment of Acute Myocardial Infarctions, Congestive Heart Failure, Acute Renal Failure and Cancer. EB 2008, San Diego, April 9, 2008
104. Update on the functions of natriuretic peptides. de Bold, A.J. XVI World Congress of Cardiology, Buenos Aires, Argentina, May 21, 2008
105. BNP is uniquely regulated during inflammation. Ogawa, T, Venoit, JP, Kuroski de Bold ML, de Bold, A J. 14th World Congress on Heart Disease, Intern Acad Cardiol Annual Scientific Sessions. Toronto, Canada, July 26-29, 2008 J Heart Disease 6(1):132, 2008
106. Transcriptional analysis of the endocrine heart under normal and chronic hemodynamic overload conditions. Forero McGrath, M. and de Bold, A.J. Functional Genomics: Towards Personalized Health Care Santorini, 21-23 September, 2008
107. Análisis transcripcional del corazón endocrino en condiciones normales y sobrecarga hemodinámica crónica. Forero McGrath, M. and de Bold, A.J. II Congreso Iberoamericano de Ciencias Fisiológicas, Pukon, Chile, 2011

INVITED LECTURES

1. Heart Atrial Myocardium. Does it have a Secretory Function? Department of Physiology, University of Toronto, Toronto, Ontario, February 1980.
2. Atrial Natriuretic Factor. Renal-Metabolic Rounds, Kingston General Hospital, Kingston, Ontario, May 21, 1982.
3. Therapeutic Drug Monitoring. Society of Clinical Chemists, San Juan, Argentina, September 29, 1982.
4. Presence of a Peptide with Diuretic and Natriuretic Properties in the Atrial Myocardium. Biology Society, Córdoba, Argentina, October 1982.
5. The Use of HPLC in the Clinical Laboratory. Department of Clinical Chemistry, Central Laboratory, Hospital Nacional de Clínicas, Córdoba, Argentina, October 5, 1982.
6. Functional Morphology in the Atrial Myocardium. Department of Physiology and Biophysics, La Plata University, La Plata, October 18, 1982.
7. Presence of a Peptide with Potent Diuretic and Natriuretic Properties in the Atrial Myocardium. Relationship with Atrial Specific Granules. Institute of Experimental Biology and Medicine,

Buenos Aires, Argentina, October 19, 1982.

8. Invited Discussant - Council for High Blood Pressure Research. American Heart Association, 36th Annual Fall Conference and Scientific Sessions, Cleveland, Ohio, October 21, 1982.
9. Discovery and Isolation of a Peptide with Potent Diuretic and Natriuretic Properties. Smith, Kline and French Laboratories, Philadelphia, Pennsylvania, December 17, 1982.
10. Discovery and Isolation of a Peptide with Potent Diuretic and Natriuretic Properties from the Mammalian Heart. Department of Biochemistry, Queen's University, Kingston, Ontario, January 28, 1983.
11. Relationships between Morphology and Function in the Atrial Myocardium. Department of Anatomy, Queen's University, Kingston, Ontario, February 14, 1983.
12. The Cardionatrin: Diuretic, Natriuretic and Hypotensive Peptides Produced by the Heart. Institute for Experimental Pharmacology, Buenos Aires, Argentina. October 24, 1983.
13. The Cardionatrin: Diuretic, Natriuretic and Hypotensive Peptides Produced by the Heart. XVth Annual Meeting for Argentina Society for Experimental Pharmacology, La Falda (Córdoba), Argentina, November 2, 1983.
14. Isolation and Purification of the Cardionatrin. Pfizer Inc., Groton, Connecticut, November 18, 1983.
15. Isolation and Purification of the Cardionatrin. Toronto Hypertension Society, Toronto, Ontario, November 15, 1983.
16. The Cardionatrin: Diuretic and Hypotensive Peptides Produced by the Heart. Department of Physiology, Queen's University, Kingston, Ontario, November 28, 1983.
17. Diuretic and Vasoactive Peptides Produced by the Heart. Heart Institute, Ottawa Civic Hospital, Ottawa, Ontario, February 1, 1984.
18. Chemistry and Biology of Peptides - ANF. Gordon Research Conference, Santa Barbara, California, February 6-10, 1984.
19. Cardionatrin: Diuretic and Vasoactive Peptides Produced by the Heart. DuPont Inc., Wilmington, Delaware, February 26, 1984.
20. Cardionatrin: A Family of Diuretic and Natriuretic Peptides Produced by the Heart. Endocrinology Lab, Royal Victoria Hospital, Montreal, Quebec, March 8, 1984.
21. Conference on Atrial natriuretic Cardionatrin Factor BioMega, Montreal, Quebec, March 9, 1984.
22. Invited Speaker. Wellington County Medical Society, Guelph, Ontario, April 18, 1984.

23. Potential of Cardionatrin in the Control of Water and Electrolyte Balance. Surgical Rounds, Kingston General Hospital, Kingston, Ontario, May 1, 1984.
24. On Hospital-Based Basic Research. Ontario Hospital Association Meeting, Kingston, Ontario, April 11, 1984.
25. Diuretic Peptides from the Heart. Joint Scientific Sessions of the Councils on Circulation and Basic Science, American Heart Association, Snowmass, Colorado, August 9-12, 1984.
26. Potencial de la Cardionatrina para el Uso Clínico. International Symposium: Encuentro con Argentinos Endocrinólogos del Exterior, Buenos Aires, Argentina, August 28, 1984.
27. Aspectos Morfológicos y Bioquímicos de las Cardionatrinas. International Symposium: Encuentro con Argentinos Endocrinólogos del Exterior, Buenos Aires, Argentina, August 30, 1984.
28. Atrial Granules-Peptide Isolation. Symposium: Atrial Natriuretic Factor: The Medium Short-Term Sodium Regulator? Annual Meeting, Canadian Society for Clinical Investigation, Montreal, September 10, 1984.
29. Morphological and Biochemical Aspects of Atrial Natriuretic Factor (Cardionatrin). International Symposium on Natural Products and Biological Activities, NAITO Foundation, Tokyo, Japan, November 5-7, 1984.
30. Atrial Natriuretic Factor (Cardionatrin): Current Status. New Endogenous Natriuretic Systems, INSERM Conferences, Seillac, France, November 11-15, 1984.
31. Atrial Natriuretic Factors. 17th Annual Meeting of the American Society of Nephrology, Washington D.C., December 9-12, 1984.
32. On Serendipity, The Shoulders of Giants and Basic Science. Canadian Federation of University Women, Queen's University, Kingston, Ontario, October 10, 1984.
33. Atrial Natriuretic Factor: An Overview. Schering-Plough Corporation, Kenilworth, New Jersey, October 19, 1984.
34. Atrial Natriuretic Factor: An Overview. International Medical Directors Meeting, Merck, Sharp & Dohme, Princeton Forrestal Center, Princeton, New Jersey, October 22, 1984.
35. Atrial Natriuretic Factor. Dept. Innere Medizin Kantonsspital, Basel, Switzerland, November 19, 1984.
36. Atrial Natriuretic Factor. Physiologisches Institut, Universität München, Germany, November 23, 1984.
37. Atrial Natriuretic Factor: An Overview. 69th Annual Meeting, Federation of American Societies for Experimental Biology, Anaheim, California, April 21-26, 1985.
38. Endocrine Function of Cardiac Muscle: ANF - From Inception to Present. Dinner meeting,

- Cardiac Muscle Society, Anaheim, California, April 24, 1985.
39. Atrial Natriuretic Factor. 9th American Peptide Symposium, Toronto, Canada, June 23-28, 1985.
 40. Atrial Natriuretic Factor. Laurentian Hormone Conference, Banff Springs, Calgary, Alberta, September 11-13, 1985.
 41. Atrial Natriuretic Factor. Foothills Hospital, University of Calgary, Calgary, Alberta, September 12, 1985.
 42. Atrial Natriuretic Factor. Monsanto Chemical Company, St. Louis, Missouri, October 22, 1985.
 43. Cardionatrin: Blood Pressure and Volume-Regulating Heart Hormones. Symposium - "Research in Action", Heart and Stroke Foundation of Ontario Toronto, Ontario, November 3, 1985.
 44. Atrial Natriuretic Factor (Cardionatrin): Polypeptide Hormone Produced by the Heart. Department of Physiology, University of Western Ontario, London, Ontario, November 4, 1985.
 45. Atrial Natriuretic Peptides. International Symposium on Atrial Natriuretic Peptides. Swiss Hypertension Workshop II, Bern, Switzerland, November 18-19, 1985.
 46. Atrial Natriuretic Factor. Centre Hospitalier Regional et Universitaire D'Amiens, Amiens, France, November 22, 1985.
 47. Cardionatrin: Pathophysiologic and Therapeutic Prospects of a Peptide Hormone Produced by the Heart. Award for Excellence In Research Lecture, Queen's University, Kingston, Ontario, February 13, 1986.
 48. Atrial Natriuretic Factor. First International Symposium on Atrial Natriuretic Factor. Clinical Research Institute of Montreal, Quebec, March 10-11, 1986.
 49. Historical Perspectives of the Atrial Granules. APS-FASEB 86, 70th Annual American Physiological Society Meeting, St. Louis, Missouri, April 14-17, 1986.
 50. Historical Review of ANF. The First World Congress on Biologically Active Atrial Peptides, Waldorf Astoria Hotel, New York, New York, May 29-June 1, 1986.
 51. Atrial Hormones and Other Natriuretic Factors. Clinical Physiology Symposium, APS-FASEB '86, April 14-17, 1986.
 52. ANF: Discovery/Innovation. Canadian Science Writers Conference, Queen's University, Kingston, Ontario, May 5, 1986.
 53. Cardionatrin. Hotel Dieu Hospital - Anaesthesia Rounds, Kingston, Ontario, May 6, 1986.

54. The Role of Basic Science in Health Care. Alumni - University of Ottawa Heart Institute, Ottawa, Ontario, May 22, 1986.
55. Functional Morphology of the Mammalian Heart Atrium. Pathology Residents' Research Day, University of Ottawa, Ottawa, Ontario, June 4, 1986.
56. An Overview of Atrial Natriuretic Factor. Pathology Department, Queen's University and Hotel Dieu Hospital, Kingston, Ontario, July 13-19, 1986.
57. Atrial Natriuretic Factor - Introductory Lecture. Symposium on Natriuretic Factors. International Union of Physiological Societies, Vancouver, B.C., July 13-19, 1986.
58. Atrial Natriuretic Factor. World Congress of Cardiology, Washington, D.C., September 15, 1986.
59. ANP Biochemistry and Molecular Biology. The Second World Congress on Biologically Active Atrial Peptides, Waldorf Astoria Hotel, New York, New York, May 18-21, 1987.
60. Factors Affecting Cardionatriin Release. First European Congress of Endocrinology, Copenhagen, June 21-25, 1987.
61. Atrial Natriuretic Peptide. Satellite Symposium on Circulating Sodium Transport Inhibitors, Natriuretic Factors and Hypertension, London, England, August 3-4, 1987.
62. A Heart-Brain Peptide: The Atrial Natriuretic Factor. Society for Neuroscience 17th Annual Meeting, New Orleans, Louisiana, November 16-21, 1987.
63. Some Recent Developments in ANF Research. The Canadian Hypertension Society, Ontario Chapter Meeting, Toronto, Ontario, June 5, 1987.
64. The Discovery of Atrial Natriuretic Factors and their Physiological Actions. ANF Symposium, Ottawa General Hospital, Ottawa, Ontario, June 10, 1987.
65. Teachings of a Hormone: The Atrial Natriuretic Factor Paradigm. Workshop On Atrial Natriuretic Factor. Interdisciplinary Study Group in Experimental Nephrology. Buffalo, New York, June 8, 1987.
66. Address to volunteers on ANF discovery. Heart and Stroke Foundation of Ontario Annual Meeting, Ottawa, Ontario, June 17, 1987.
67. Atrial Natriuretic Factor. Xth International Congress of Nephrology, London, England, July 26-31, 1987.
68. Atrial Natriuretic Peptide. Satellite Symposium of the Xth International Congress of Nephrology: Circulating Sodium Transport Inhibitors, Natriuretic Factors and Hypertension, London England, August 3-4, 1987.
69. Functional Morphology of ANF Release. UCLA Symposia, Steamboat Springs, Colorado,

January 17-23, 1988.

70. The Atrial Natriuretic Factor Paradigm. Medical Scientist Training Program. The University of Iowa, Cedar Rapids, Iowa, March 8- 9, 1988.
71. ANF - An Overview and Control of Release. University of Western Ontario, 1988 Biological Colloquium, Distinguished Visitors Series, London, Ontario, March 23, 1988.
72. Atrial Natriuretic Factor: A Hormone From the Heart. People and Ideas in Endocrinology, FASEB, New Orleans, Louisiana, March 19-23, 1989.
73. Studies on In Vivo and In Vitro ANP Production. ANP and Related Peptides Symposia. International Congress of Congress of Physiological Science, Helsinki, Norway, July 9-14, 1989.
74. Regulation of Atrial Natriuretic Factor (ANF) Production, Fifth Annual Merck, Sharp and Dohme Lecture, Cleveland Clinic Foundation, Cleveland, Ohio, February 15, 1990.
75. Acople Estiramiento-Secreción en Cardiocitos Auriculares. Papel No Esencial Del Calcio En La Liberación Del Factor Natriurético Auricular. Instituto de Investigaciones Farmacológicas. Conicet Jornada Científica en el 20^o. Aniversario de su Creación, Buenos Aires, Argentina, May 1988.
76. Heart and Stroke Foundation of Ontario. After Dinner Speech to Area Volunteers in Golf Tournament, Manderley Golf Course, Ottawa, Ontario, May 23, 1990.
77. On the Payoff of Basic Science. Algoma Chapter, Sault St. Marie, Heart and Stroke Foundation of Ontario, June 5, 1990.
78. Heart and Stroke Foundation of Ontario, Luncheon Speaker, Ottawa Chapter, Chimo Inn, Ottawa, Ontario, June 27, 1990
79. Atrial Natriuretic Factor: A Heart Hormone Modulatory of Blood Pressure and Volume, The 1st Irvine H. Page International Hypertension Research Symposium, Baltimore, Maryland, September 12, 1990
80. Factor Natriurético Atrial. III Congreso Argentino de Protozoología y Reunión Sobre Enfermedad de Chagas, Buenos Aires, November 18-20, 1990.
81. Fisiología y Patofisiología del Factor Natriurético Atrial. XXXV Reunión de La Sociedad Argentina de Investigación Clínica. Mar del Plata, November 21-24, 1990.
82. Factor Natriurético Atrial: Desde su Descubrimiento a la Clínica en Diez Años. Academia de Ciencias, Córdoba, November 29, 1990.
83. Relación Entre la Función Endocrina y Muscular en el Cardiocito Atrial. Sociedad de Biología de Córdoba, Instituto Martin y Mercedes Ferreyra, Córdoba, November 30, 1990.

84. Impact of Research on the Reduction of Heart Disease and Stroke. Guest Speaker, Glengarry Chapter Annual Meeting, Heart and Stroke Foundation of Ontario, May 29, 1991.
85. Therapeutic Modalities Derived from ANF. Ottawa Heart Institute/Pfizer Symposium "Cardiovascular Research: From Bench to Bedside", October 1991.
86. Morphological and Biochemical Aspects of Natriuretic Peptide Biosynthesis and Release by Atrial Cardiocytes. UCSD Asilomar Conference. Molecular and Cellular Biology of the Cardiac Myocyte, Pacific Grove, California, November 17-20, 1991.
87. Recent Advances in Natriuretic Peptide Research, Health Sciences Faculty, Fundación Barceló, Buenos Aires, Argentina Nov 11, 1992.
88. Therapeutic Modalities Derived from Natriuretic Peptides. Health Sciences Faculty, Fundación Barceló, Buenos Aires, Argentina Nov 11, 1992.
89. Functional Morphology of the Endocrine Heart. Institute for Cell Biology, National University of Buenos Aires, Buenos Aires Nov. 12, 1992.
90. Recent Advances in Natriuretic Peptide Research. Annual Meeting of the Argentinian Council for High Blood Pressure, Mar del Plata, Nov 14, 1992.
91. Therapeutic Modalities Derived from Natriuretic Peptides. Annual Meeting of the Council for High Blood Pressure, Mar del Plata, Nov 14, 1992.
92. Therapeutic Modalities Derived from Natriuretic Peptides. Cardiology Division, Argerich Hospital, Buenos Aires, Nov 16, 1992.
93. Therapeutic Modalities Derived from Natriuretic Peptides Cardiology Division, Hospital Italiano. Buenos Aires, Nov 18, 1992.
94. Significance and Application of the ANF Discovery. Paraná Heart foundation, Paraná, Argentina, Nov 30, 1992.
95. Pathophysiological Expression of Natriuretic Peptides. Distinguished Lectures Series, Department of Pathology and Laboratory Medicine, St. Paul's Hospital and the University of British Columbia, Vancouver, October 28, 1993.
96. Pathophysiological Expression of Genes Encoding for Natriuretic Peptides. Special Academic Convocation to receive the title of Honourary Professor National University of Buenos Aires, Argentina, November 9, 1993.
97. Pharmacology of Natriuretic Peptides. Instituto de Nefrología Lanari, Buenos Aires, Argentina, November 11, 1993.
98. DNA Amplification by the Polymerase Chain Reaction: Research and Clinical Applications College of Clinical Biochemists, Paraná, Argentina, November 15, 1993.

99. Participant in Research Funding and Administration Day Seminar Parana Heart Foundation, November 16, 1993.
100. Latest advances in ANF Research. Medical Association of Entre Rios, November 18, 1993.
101. Commercialization of Drug Discoveries: Experiences of an Academic Exposcience, Buenos Aires, November 29, 1993.
102. The Endocrine Function Of The Heart. YMCA Friday Luncheon and Discussion Club, Ottawa, April 8, 1994.
103. Participation of Natriuretic Peptides in the Mineralocorticoid Escape Phenomenon. 3rd Scientific Meeting, Medical Association of the Midwest-Rush-Presbyterian-St. Luke's Medical Center, Bay City, Michigan, April 23, 1994.
104. Stretch-Induced Release of ANF. Session on Electro-Mechanical Cross-Talk in the Heart, XIIth World Congress of Cardiology Berlin, September 10-14, 1994.
105. Mechanical and Neuroendocrine Control of Cardiac Natriuretic Peptide Gene Expression 18th Meeting of the European Working Group on Cardiac Cellular Electrophysiology Papendal, Arnhem, The Netherlands, September 16-18, 1994.
106. Physiological and Pathophysiological Cardiac Natriuretic Peptide Gene Expression Istituto di Fisiologia Clinica del CNR, Pisa, Italy, September 21, 1994.
107. Practical Issues of Commercialization in Basic Science: An Example With The ANF Discovery. Organization of American States and Embassy of Argentina-Sponsored Symposium. International Development Bank. Washington, DC, November 1994.
108. Cellular Basis of the Integrative Function of the Endocrine Heart Under Physiological and Pathophysiological Conditions. Meeting of the National Cardiology Society, Paraná, Argentina, May 25-27, 1995.
109. Natriuretic Peptide Plasma Levels: A Reflection of Acute and Chronic Hemodynamic Load Meeting of the National Cardiology Society, Paraná, Argentina, May 25-27, 1995.
110. Cellular Basis for The Integrative Function of The Endocrine Heart. The University of Ottawa Heart Institute at the Ottawa Civic Hospital Seminar Series, 1995.
111. Measurement of Different Natriuretic Peptide Fragments in Plasma: An Attractive Alternative in Clinical Cardiology. Opening Lecture, Congress of Clinical Biochemistry, Santa Fe, Argentina, October 10 1996.
112. The Physiology and Pathophysiology of the Endocrine Heart The Cordoba Medical Academy, November 1996.
113. The Function of the Endocrine Heart in Cardiovascular Homeostasis International Medical

- Student Congress, Cordoba, Argentina, October 18, 1996.
114. Messages From The Heart. Presentation to The Round Table, Rideau Club, March 27, 1996.
 115. Cardiac Natriuretic Peptide Gene expression and Cardiovascular Homeostasis. The University of Edmonton Health Sciences Complex, Alberta, March 25, 1996.
 116. Specific Changes In Translational, Postranslational, Storage and Release Events Associated with Various Mechanical and Neuroendocrine Stimuli of Cardiac Natriuretic (NP) Production. Opening Lecture of Symposium on Cardiac Peptides and Receptor Guanylate Cyclases, Meeting of the Union des Sociétés Suisses de Biologie Expérimentale, Geneva, March 20, 1997.
 117. Interscientia, a Ciberjournal. Workshop on Hemispheric Collaboration in Science. The Fifth Chemical Congress of North America, Cancun, México, November 11, 1997.
 118. Networking Academics Through the Internet. The Interscientia Experience. Symposium on Internet in the Americas. The Fifth Chemical Congress of North America, Cancun, México, November 15, 1997.
 119. The Houssay Lecture (In commemoration of the 50th Anniversary of the Nobel Prize to A. Houssay) University of Buenos Aires, November, 1997.
 120. Opening Lecture. Meeting of Argentinean Federation of Cardiologists and the Entre Rios Cardiology Society, Parana, Argentina, December 7, 1997.
 121. Overview of Natriuretic Peptides: Insights Into their Production Regulation Peptides Through *In Vivo* and *In Vitro* Model Stimuli. Opening Lecture of Symposium on Natriuretic peptides and their Pathophysiology. III International Congress of Pathophysiology, Lahti, Finland, June 29, 1998.
 122. Physiology of Natriuretic Peptides. Myoshin Ji Symposium “Frontiers in Cardiovascular Research”, Satellite of the International Symposium of Cardiovascular Endocrinology and Metabolism., Kyoto, Japan, November 29, 1998.
 123. Cellular Basis of the Endocrine Heart. Department of Cell Biology. University of Medicine and Dentistry of New Jersey, June 14, 1999.
 124. Natriuretic Peptides: Omnipresent Cardiovascular Sentinels Of Cardiovascular Function and Growth. VI International Meeting of the International Society for Heart Research. Buenos Aires, May 21, 1999.
 125. Central Volume Regulation and Natriuretic Peptides. 4th International Congress of Head-Out Water Immersion, Karl Frazen University, Graz, Austria, September 27-28, 1999.
 126. Competitivity in Science. 60th Anniversary of *Medicina*. Symposium on Clinical Investigation In the New Milenium. National Academy of Medicine. Buenos Aires, Argentina. October 6-7, 1999.

127. Cardiac Natriuretic Peptides. 50th Anniversary of the Faculty of Medicine of the Universidad Nacional de Tucumán. 1 4-16 October, 1999. Tucumán, Argentina.
128. The Application of Knowledge in the Advancement Of Science. Social and Educational Basis. 50th Anniversary of the Faculty of Medicine of the Universidad Nacional de Tucumán. 14-16 October, 1999. Tucumán, Argentina.
129. Competitiveness In Science. CEPROCOR, Punilla, Cordoba, Argentina. October 19, 1999.
130. The Endocrine and the Cardiac Cytokine Network. Satellite Symposium of the European Society of Hypertension Meeting, Oulu, Finland, 2000.
131. Modulation of the Endocrine Function of the Heart. The Merck Lecture. The Lerner Research Institute Department of Molecular Cardiology, The Cleveland Clinic Foundation. Cleveland, Ohio, October 17, 2000.
132. The ANF Family of Natriuretic Peptides: A Look into their Role in Health and Disease 20 years after their Discovery. Landmark Lecture. XVII World Congress of the International Society for Heart Research. Winnipeg, July 11, 2001.
133. Common Strategies in Education and Science in G7 countries. Lectures during the celebration of the 125th Anniversary of the creation of the Faculty of Medicine of the National University of Córdoba, Argentina. Córdoba , Argentina, October 10, 2002.
134. Highlighted Lecture. Pathophysiology and Clinical Relevance of the Natriuretic Peptides. XXIX Congress of Cardiology. Buenos Aires, Argentina, October 14, 2002.
135. Round Table. Natriuretic Peptides in Heart Failure. XXIX Congress of Cardiology. Buenos Aires, Argentina, October 15, 2002.
136. Education and Science in “First World” Countries. Lectures to Senior High School Students from three institutions. Paraná, Argentina October 22-25, 2002.
137. Common Strategies in Education and Science in G7 countries. Congress of Interventional Cardiologist. Tanti, Córdoba, Argentina. October 3, 2002.
138. Physiology and Pathophysiology of Natriuretic Peptides. Symposium on the Ischemic Heart. Santiago, Dominican Republic, February 7-8, 2003.
139. The Discovery of Atrial Natriuretic Factor. 14th Annual University of Alabama at Birmingham Vascular Biology and Hypertension Symposium. Sandestin Resort, Florida, October 9-12, 2003.
140. Mechanisms of BNP signaling. Fourteenth Annual University of Alabama at Birmingham Vascular Biology and Hypertension Symposium. Sandestin Resort, Destin, Florida, October 9-12, 2003.

141. Physiological and Pathophysiological Aspects of Natriuretic Peptide Production. First World Congress of the International Academy of Cardiovascular Sciences. Belo Horizonte, Brazil, October 11-15, 2003.
142. Clinical Relevance of the Endocrine Heart. Research Day of the Faculty of Medicine of the University of Cordoba, Argentina. December 4, 2003.
143. Policy and Strategy in the Formation of Human Resources for Research in Medicine. Research Day of the Faculty of Medicine of the University of Cordoba, Argentina. December 4, 2003.
144. Modulation of Natriuretic Peptide Gene Expression by Cytokines. Symposium on Molecular Physiology of Vasoactive Peptides. Argentinean Society for Clinical Investigation and North-South Initiative, American Physiological Society. Mar del Plata, Argentina, November 19, 2003.
145. The Endocrine Function of the Heart. Federation of Endocrine Societies of Argentina. Cordoba, Argentina, November 6, 2004.
146. Function of Natriuretic Peptides in the Integration of Cardiovascular Endocrinology. Federation of Endocrine Societies of Argentina. Cordoba, Argentina, November 7, 2004.
147. Lecture to undergraduate students on academic competitiveness. Colegio D.F. Sarmiento, Paraná, Argentina November 15, 2004.
148. The Discovery of ANF. Lecture to Graduate Students, Post Doctoral Fellows and young Clinical Staff. Miyazaki Medical School. Miyazaki, Japan, November 24, 2004.
149. Role of G-protein Signaling in Natriuretic Peptide Production. Eighth Scientific Meeting of the Society of Cardiovascular Endocrinology and Metabolism. Miyazaki, Japan November 25, 2004.
150. COE International Symposium on Recent Advances in Biologically Active Peptides. Miyazaki, Japan, November 27, 2004.
151. Natriuretic Peptide Secretion Signaling. Experimental Biology 2005. San Diego, California, April 2005.
152. Cardiac Hormones and Inflammation. 16th World Congress of Cardiothoracic Surgeons, Ottawa, Ontario. August 16-18, 2006.
153. Inflammation and the endocrine Heart. Fifth Oulu Symposium on "Advances in Molecular and Cellular Biology of Vasoactive Factors" Finland, September 9, 2006.
154. Inflammation and Natriuretic Peptide Expression. International Society for Hypertension. Fukuoka, Japan, 2006.
155. Un viaje con Sarmiento por Canadá, Estados Unidos, Rusia y Argentina. Conferencia

- Inaugural. Fundación para la Educación en Ciencia. Paraná, Entre Ríos, Argentina, May 2007.
156. El Ayer y Hoy del Factor Natriurético Atrial. Conferencia a CUBRA IX. Carlos Paz, Córdoba, Argentina, September 2007.
157. Protein-Protein Interactions and Natriuretic Peptides. International Congress on Vasoactive Peptides. Ouro Preto, MG, Brazil, February 2008.
158. International Congress of Cardiology. Update in the functions of natriuretic peptides. Buenos Aires, Argentina, May 2008.
159. "G alpha O and proANF: partners in storage targeting to specific atrial granules" 6th Oulu symposium on vasoactive factors, Vuokatti, Finland, April 2009.
160. Regulation of the secretory function of the heart: a new paradigm. University of Ottawa Heart Institute. April, 2009.
161. "Biological Basis in the use of ANF and BNP as Biomarkers of Cardiac Disease". Universidad MacKenzie, Sao Paulo, Brazil, November 3, 2009.
162. Bases Biológicas del uso de ANF y BNP como Biomarcadores de Enfermedad Cardiaca. Hospital de Clinicas, Universidad Nacional de Asuncion, Paraguay, November 5, 2009
163. Competitividad en educación y ciencia. Universidad Católica de Asuncion, Asuncion, Paraguay, November 6, 2009.
164. Latest development on the endocrine heart. Veterinary College of Villa del Rosario. Cordoba, Argentina, November 17 2009.
165. Competitividad Internacional en Ciencia y Tecnología: Un desafío ineludible. CONSEJO ARGENTINO PARA LAS RELACIONES INTERNACIONALES (CARI), Buenos Aires, March 9, 2010.
166. Hemodynamic and inflammatory factors influencing the function of the endocrine heart. Clinical implications. Argentinean Union of Clinical Biochemists (CUBRA XI) October 8, 2011, Jujuy, Argentina.
167. Heterotrimeric G protein secretion pathways in atrial cardiomyocytes. Oulu Symposium in Advances in Molecular Mechanisms of Heart Failure and Myocardial Repair & natriuretic Peptides. University of Oulu, Finland, August 31, 2012.
168. Inductee ceremony lecture. Un paradigma transmutado: el corazón como glándula de secreción endocrina. National Academy of Sciences, Cordoba, Argentina, March 2013.
169. Master lecture. Evolution of the functional paradigm of the heart. Faculty of Medicine, Hospital Nacional de Clinicas, Cordoba, Argentina, October 22, 2013.

170. Master Lecture. Biology of the natriuretic peptides. II Department of medicine, Graduate Studies Auditorium, Faculty of Medicine, National University of Cordoba, Cordoba, Argentina, October 23, 2013.
171. Natriuretic peptides: from its discovery to their present therapeutic use. Sanatorio Allende, Cordoba, Argentina, October 23, 2013.
172. Natriuretic peptides and inflammation. National Academy of Sciences, Cordoba, Argentina, October 24, 2013.
173. New aspects of natriuretic peptides in cardiology. Cardiology Society of Cordoba, Sheraton Hotel, Argentina, October 25th, 2013.
174. G protein- and cytokine-mediated pathways to natriuretic peptide stimulated secretion. Brazilian Congress of Pharmacology, Fortaleza, Brazil. October 2014.
175. The 30th Anniversary of ANP (Atrial Natriuretic Peptide) Discovery Lecture. Kyoto, Japan, September 2014.